



HU000035044T2

(19) **HU**(11) Lajstromszám: **E 035 044**(13) **T2****MAGYARORSZÁG****Szellemi Tulajdon Nemzeti Hivatala**

EURÓPAI SZABADALOM SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 10 189868**(51) Int. Cl.: **C07K 14/47** (2006.01)(22) A bejelentés napja: **2004. 05. 19.****C12N 15/10** (2006.01)

(96) Az európai bejelentés bejelentési száma:

EP 20040189868

(97) Az európai bejelentés közzétételi adatai:

EP 2361928 A1 **2011. 08. 31.**

(97) Az európai szabadalom megadásának meghirdetési adatai:

EP 2361928 B1 **2017. 04. 26.**

(30) Elsőbbségi adatok:

471929 P **2003. 05. 19.** **US**

(72) Feltaláló(k):

Chilcote, Tamie J., San Francisco, CA 94116 (US)**Goldstein, Jason, Burlingame, CA 94010 (US)****Gai, Wei Ping, Bedford Park, South Australia 5042 (AU)****Anderson, John P., San Francisco, CA 94115 (US)**

(73) Jogosult(ak):

**Prothena Biosciences Limited, Co. Dublin A96
T927 (IE)****The Flinders University of South Australia,
Adelaide SA 5001 (AU)**

(74) Képviselő:

**Danubia Szabadalmi és Jogi Iroda Kft.,
Budapest**

(54)

Alfa-szinuklein csonkolt fragmensei Lewy-testes betegségben

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 361 928 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
26.04.2017 Bulletin 2017/17

(51) Int Cl.:
C07K 14/47 (2006.01) C12N 15/10 (2006.01)

(21) Application number: **10189868.2**

(22) Date of filing: **19.05.2004**

(54) **Truncated fragments of alpha-synuclein in Lewy body disease**

Verkürzte Alpha-Synuklein-Fragmente in der Lewy-Körper-Krankheit

Fragments tronqués d'alpha-synucléines dans une maladie de corps de Lewy

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PL PT RO SE SI SK TR**

(30) Priority: **19.05.2003 US 471929 P**

(43) Date of publication of application:
31.08.2011 Bulletin 2011/35

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
04776059.0 / 1 633 189

(73) Proprietors:
• **Prothena Biosciences Limited**
Co. Dublin A96 T927 (IE)
• **The Flinders University of South Australia**
Adelaide SA 5001 (AU)

(72) Inventors:
• **Chilcote, Tamie J.**
San Francisco, CA 94116 (US)
• **Goldstein, Jason**
Burlingame, CA 94010 (US)
• **Gai, Wei Ping**
Bedford Park, South Australia 5042 (AU)
• **Anderson, John P.**
San Francisco, CA 94115 (US)

(74) Representative: **Goodfellow, Hugh Robin**
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA (GB)

(56) References cited:

- **CROWTHER R A ET AL: "Synthetic filaments assembled from C-terminally truncated alpha-synuclein", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 436, no. 3, 9 October 1998 (1998-10-09), pages 309-312, XP004258443, ISSN: 0014-5793, DOI: DOI:10.1016/S0014-5793(98)01146-6**
- **MORT J S ET AL: "The use of cleavage site specific antibodies to delineate protein processing and breakdown pathways", MP. MOLECULAR PATHOLOGY, BMJ PUBLISHING GROUP, LONDON, GB, vol. 52, no. 1, 1 February 1999 (1999-02-01), pages 11-18, XP002670376, ISSN: 1366-8714, DOI: 10.1136/MP.52.1.11**
- **Greer M Murphy ET AL: "Copynlight American Society for Investigative Pathology Development of a Monoclonal Antibody Specific for the COOH-Terminal of f3-Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders", American Journal of Pathology, 1 May 1994 (1994-05-01), XP055307036, Retrieved from the Internet: URL: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1887348/pdf/amjpathol00065-0242.pdf> [retrieved on 2016-09-30]**
- **JARMILA JANATOVA: "C3, C5 components and C3a, C4a, and C5a fragments of the complement system", METHODS IN ENZYMOLOGY, vol. 162, 1 January 1988 (1988-01-01), pages 579-625,**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 361 928 B1

Description

BACKGROUND

[0001] Lewy body diseases (LBDs) are characterized by degeneration of the dopaminergic system, motor alterations, cognitive impairment, and formation of Lewy bodies (LBs). (McKeith et al., Clinical and pathological diagnosis of dementia with Lewy bodies (DLB): Report of the CDLB International Workshop, Neurology (1996) 47:1113-24). LBDs include Parkinson's disease, Diffuse Lewy body disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), and combined PD and Alzheimer's disease (AD). Dementia with Lewy bodies (DLB) is a term coined to reconcile differences in the terminology of LBDs. Disorders with LBs continue to be a common cause for movement disorders and cognitive deterioration in the aging population (Galasko et al., Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch. Neurol. (1994) 51:888-95). Although their incidence continues to increase creating a serious public health problem, to date these disorders lack approved treatments (Tanner et al., Epidemiology of Parkinson's disease and akinetic syndromes, Curr. Opin. Neurol. (2000) 13:427-30). The cause for LBD's is controversial and multiple factors have been proposed to play a role, including various neurotoxins and genetic susceptibility factors.

[0002] AD, PD, and DLBD are the most commonly found neurodegenerative disorders in the elderly. Recent epidemiological studies have demonstrated a close clinical relationship between AD and PD, as about 30% of Alzheimer's patients also have PD. Compared to the rest of the aging population, patients with AD are thus more likely to develop concomitant PD. Furthermore, PD patients that become demented usually have developed classical AD. Although each neurodegenerative disease appears to have a predilection for specific brain regions and cell populations, resulting in distinct pathological features, PD, AD, and DLBD also share common pathological hallmarks. Patients with familial AD, Down syndrome, or sporadic AD develop LBs on the amygdala, which are the classical neuropathological hallmarks of PD. Additionally, each disease is associated with the degeneration of neurons, interneuronal synaptic connections and eventually cell death, the depletion of neurotransmitters, and abnormal accumulation of misfolded proteins, the precursors of which participate in normal central nervous system function. Biochemical studies have confirmed a link between AD, PD and DLB.

[0003] In recent years, new hope for understanding the pathogenesis of LBD has emerged. Specifically, several studies have shown that the synaptic protein alpha-synuclein plays a central role in PD pathogenesis since: (1) this protein accumulates in LBs (Spillantini et al., Nature (1997) 388:839-40; Takeda et al., J. Pathol. (1998) 152:367-72; Wakabayashi et al., Neurosci. Lett. (1997) 239:45-8), (2) mutations in the alpha-synuclein gene co-segregate with rare familial forms of parkinsonism (Kruger et al., Nature Gen. (1998) 18:106-8; Polymeropoulos, et al., Science (1997) 276: 2045-7) and, (3) its overexpression in transgenic mice (Masliah et al., Science (2000) 287:1265-9) and *Drosophila* (Feany et al., Nature (2000) 404:394-8) mimics several pathological aspects of PD. Thus, the fact that accumulation of alpha-synuclein in the brain is associated with similar morphological and neurological alterations in species as diverse as humans, mice, and flies suggests that this molecule contributes to the development of PD.

[0004] The neuritic plaques that are the classic pathological hallmark of AD consist essentially of amyloid beta (A β) peptide, an amino acid proteolytic product of the amyloid precursor protein (APP), and NAC, a 35 amino acid proteolytic fragment of alpha-synuclein. Both A β and NAC were first identified in amyloid plaques as proteolytic fragments of their respective full-length proteins, for which the full-length cDNAs were identified and cloned. (Iwai A., Biochim. Biophys. Acta (2000) 1502:95-109); Masliah et al., AM. J. Pathol (1996) 148:201-10; Ueda et al., Proc. Natl. Acad. Sci. USA (1993) 90:11282-6).

[0005] Alpha-synuclein is part of a large family of proteins including beta- and gamma-synuclein and synoretin. Alpha-synuclein is expressed in the normal state associated with synapses and is believed to play a role in neural plasticity, learning and memory. Mutations in human (h) alpha-synuclein that enhance the aggregation of alpha-synuclein have been identified (Ala30Pro and Ala53Thr) and are associated with rare forms of autosomal dominant forms of PD. The mechanism by which these mutations increase the propensity of alpha-synuclein to aggregate are unknown.

SUMMARY OF THE CLAIMED INVENTION

[0006] The invention provides an antibody that specifically binds to a 1-122 or 1-119 fragment of alpha-synuclein, without specifically binding to full-length alpha-synuclein as defined in SEQ ID No.1, or a fragment that induces this antibody wherein the fragment that induces the antibody has less than 20 amino acids of alpha-synuclein and includes the C-terminus of the 1-122 or 1-119 fragment of alpha-synuclein.

[0007] The invention also provides a fragment of full-length alpha-synuclein as defined in SEQ ID No.1, which is alpha-synuclein 1-122 or 1-119. The fragment of alpha-synuclein may bear a mutation associated with a hereditary Lewy Body Disease (LBD), optionally an A53T mutation.

[0008] The invention further provides *in vitro* methods of screening for an agent having a pharmacological activity useful for treating a Lewy Body Disease (LBD), comprising contacting the agent with an alpha-synuclein 1-122 or 1-119

fragment of the invention,; and determining the rate or extent of aggregation of the fragment of alpha-synuclein, wherein a reduction in the rate or extent of aggregation relative to a control lacking the agent indicates the agent has the pharmacological activity.

[0009] The invention further provides *in vitro* methods of screening an agent for a pharmacological activity useful in treating a LBD (e.g., Parkinson's disease or DLBD), comprising contacting a cell expressing alpha-synuclein and processing the alpha-synuclein into an alpha-synuclein 1-122 or 1-119 fragment of the invention with an agent. One then determines a level of the fragment in the cell relative to a baseline level in the same cell type in the absence of the agent, a reduction in the level of the fragment relative to the baseline indicating the agent has the pharmacological activity useful in treating a LBD. The cell can be a human cell, a neuronal cell or a dopaminergic cell. Optionally, the cell is a PC 12 or Sy5Y cell.

[0010] The invention further provides methods of screening for an agent having a pharmacological activity useful for treating a LBD (e.g., Parkinson's disease or DLBD), comprising contacting a non-human transgenic animal expressing an alpha-synuclein 1-122 or 1-119 fragment of the invention with the agent; and determining a level of aggregated forms of the fragment in the brain of the transgenic animal relative to a baseline level of aggregated forms of the fragment in a comparable transgenic animal in the absence of the agent, a reduction in the level of the aggregated forms fragment relative to the baseline indicating the agent has a pharmacological activity useful in treating a LBD. Optionally, the transgenic animal is a rodent. The transgenic animal can also be a *Drosophila*.

[0011] The invention further provides methods of screening an agent for a pharmacological activity useful for treating a LBD (e.g., Parkinson's disease or DLBD), comprising contacting a non-human transgenic animal having a transgene expressing alpha-synuclein and processing the alpha-synuclein into an alpha-synuclein 1-122 or 1-119 fragment of the invention with an agent,; and determining a level of the fragment in a neuronal cell relative to a baseline level in the absence of the agent, a reduction in the level of the fragments relative to the baseline indicating the agent has the pharmacological activity useful for treating the LBD. Optionally, the transgenic animal is a rodent, mouse or *Drosophila*.

[0012] The invention further provides a transgenic non-human animal having a genome comprising a transgene comprising a promoter operably linked to a nucleic acid segment encoding an alpha-synuclein 1-122 or 1-119 fragment of the invention; wherein expression of the fragment in the transgenic animal disposes the animal to develop at least one characteristic of a LBD. Optionally, the promoter is a PDGF promoter. Optionally, at least one characteristic is an impairment of motor function. Optionally, at least one characteristic of the transgenic animal is an impairment of cognitive function. Optionally, the transgenic animal is a rodent, mouse or *Drosophila*.

[0013] The invention further provides *in vitro* methods of detecting presence or susceptibility to an LBD in a patient, comprising detecting a level of an alpha-synuclein 1-122 or 1-119 fragment of the invention in a sample of cerebrospinal fluid, a level greater than a baseline level in undiseased individuals indicating presence or susceptibility to LBD.

[0014] As described above, the invention provides an antibody that specifically binds to a fragment of alpha-synuclein. Optionally, the antibody is a human, humanized, chimeric antibody. Optionally, the antibody is monoclonal. Optionally, the antibody has human isotype IgG1.

[0015] The antibody may be for use in diagnosing presence or susceptibility to a LBD, wherein the antibody is to be administered to a patient and the level of binding of the antibody in the patients is to be determined, wherein a higher level of binding relative to a base line level in undiseased individuals indicates presence or susceptibility to the LBD.

[0016] The alpha-synuclein 1-122 or 1-119 fragment of the invention may be for use in a method of effecting treatment or prophylaxis of a LBD, comprising administering to a patient suffering from or at risk of a LBD, an effective regime of the fragment of alpha-synuclein. Optionally, the method further comprises administering an adjuvant that augments an immune response comprising antibodies to the fragment. Optionally, the fragment is linked to a carrier forming a fusion protein, wherein the carrier augments an immune response comprising antibodies to the fragment.

[0017] The antibody of the invention may be for use in a method of effecting treatment or prophylaxis of a LBD. The method involves administering to a patient suffering from or at risk of a LBD an effective regime of the antibody, whereby the antibody effects prophylaxis or treatment of the disease.

[0018] The invention further provides a method of screening for a protease that cleaves intact alpha-synuclein to form an alpha-synuclein 1-122 or 1-119 fragment, comprising identifying an inhibitor of the protease; contacting the inhibitor with a cellular or tissue extract containing the protease, whereby the protease binds to the inhibitor; and releasing the protease from the inhibitor. Optionally, the inhibitor is a peptide of alpha-synuclein comprising a contiguous segment of at least 5 residues of intact alpha-synuclein between positions 115 and 130. Optionally, the peptide comprises a contiguous segment of at least 5 residues between positions 118 and 122. Optionally, at least one of the residues is a transition state analog.

[0019] The disclosure further provides a monoclonal antibody that specifically binds to an epitope within residues 109-120 of alpha synuclein. Optionally, the monoclonal antibody is chimeric, humanized or human.

[0020] The disclosure further provides a monoclonal antibody that specifically binds to an epitope within residues 115-123 of alpha synuclein.

[0021] The disclosure further provides a monoclonal antibody that specifically binds to a discontinuous epitope within

residues 43-51 and 58-65 of alpha synuclein. Optionally, the antibody is chimeric, humanized or human.

[0022] The disclosure further provides an end-specific monoclonal antibody that specifically binds to isolated full-length alpha-synuclein having a free C-terminus without specifically binding to a fusion protein comprising alpha synuclein having a C-terminus linked to a second polypeptide. Optionally, the antibody is chimeric, humanized or human.

[0023] The disclosure further provides methods of detecting presence or susceptibility to a Lewy body disease in a patient. The methods involve determining a level of alpha-synuclein phosphorylated or nitrated at position 125 of alpha-synuclein in a sample from a brain of the patient, an elevated level relative to the mean level in a population of undiseased individuals indicating the patient has or is susceptible to a Lewy body disease.

BRIEF DESCRIPTION OF THE FIGURES

[0024]

Figs. 1A and B show a Western blot of various extracts from the cortex and hippocampus of a transgenic mouse (B) and a matched control (A) with a polyclonal antibody that binds to an epitope within SN115-122.

Fig. 2 shows a Western blot with the same antibody as Figs. 1A and B to compare the level of the truncated form of alpha-synuclein in Triton-X100 extractions of the cortex and hippocampus mice of 3 months and 12 months in age.

Figs. 3A and B shows a Western blot with a different antibody termed 12C1 (a monoclonal binding to epitope at amino acids 43-51 and 58-65) of a Triton extracts from the brain of a transgenic mouse three months old (B) compared with an aged matched control (A).

Fig. 4 shows a further Western blot using the same antibody as Fig. 3 on a Triton extract from the brain of transgenic mice of three and twelve months of age.

Figs. 5A, B, C, D, E show Western blots with four different antibodies (B, C, D, E) and an epitope map (A) of the binding sites of the antibodies to various extracts from the brains of transgenic mice.

Figs. 6A, B, C shows Tris extracts of the brain of a patient with Lewy body disease probed with three different antibodies (A, B, C), subject to 2-D gel electrophoresis and subjected to Western blotting.

Fig. 7A, B, C, D shows additional blots of Tris extracts of the brain of a patient with Lewy body disease with four antibodies (A, B, C, D) of additional specificities.

Fig. 8 summarizes the sites of cleavage relative to the epitopes bound by antibodies used in the Western blotting.

Figs. 9A, B compares the Tris soluble proteins (A) with proteins extracted from Lewy bodies (B) by 2D electrophoresis and Western blotting.

Figs. 10A, B, C, D shows the immunoblots of proteins from Lewy bodies reprobed with various C-terminal antibodies.

Figs. 11 shows Western blots of various extracts of an undiseased and Contursi patient probed with an antibody recognizing either total alpha synuclein or specific for phospho-129 alpha synuclein.

DEFINITIONS

[0025] The term "agent" is used to describe a compound that has or may have a pharmacological activity. Agents include compounds that are known drugs, compounds for which pharmacological activity has been identified but which are undergoing further therapeutic evaluation, and compounds that are members of collections and libraries that are to be screened for a pharmacological activity.

[0026] A "pharmacological" activity means that an agent exhibits an activity in a screening system that indicates that the agent is or may be useful in the prophylaxis or treatment of a disease. The screening system can be in vitro, cellular, animal or human. Agents can be described as having pharmacological activity notwithstanding that further testing may be required to establish actual prophylactic or therapeutic utility in treatment of a disease.

[0027] In the context of molecular weight determinations based on gel electrophoresis, the term "about" indicates the standard deviation of molecular weight expected due to experimental error in repetitions of the method under the same conditions. The molecular weight determination of 12 kDa for certain fragments of alpha-synuclein applies to determi-

nations using a tryptic buffer.

[0028] The phrases "specifically binds" refers to a binding reaction which is determinative of the presence of the protein in the presence of a heterogeneous population of proteins and other biologics. Thus, under designated conditions, a specified ligand binds preferentially to a particular protein and does not bind in a significant amount to other proteins present in the sample. A molecule such as antibody that specifically binds to a protein often has an association constant of at least 10^6 M^{-1} or 10^7 M^{-1} , preferably 10^8 M^{-1} to 10^9 M^{-1} , and more preferably, about 10^{10} M^{-1} to 10^{11} M^{-1} or higher. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See, e.g., Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity.

[0029] For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

[0030] Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (see generally Ausubel *et al.*, *supra*).

[0031] Another example of algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul *et al.*, *J. Mol. Biol.* 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al.*, *supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. For identifying whether a nucleic acid or polypeptide is within the scope of the invention, the default parameters of the BLAST programs are suitable. The BLASTN program (for nucleotide sequences) uses as defaults a word length (W) of 11, an expectation (E) of 10, $M=5$, $N=-4$, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a word length (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix. The TBLASTN program (using protein sequence for nucleotide sequence) uses as defaults a word length (W) of 3, an expectation (E) of 10, and a BLOSUM 62 scoring matrix. (see Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 (1989)).

[0032] In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, *Proc. Nat'l. Acad. Sci. USA* 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability ($P(N)$), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

[0033] For purposes of classifying amino acids substitutions as conservative or non-conservative, amino acids are grouped as follows: Group I (hydrophobic sidechains): norleucine, met, ala, val, leu, ile; Group II (neutral hydrophilic side chains): cys, ser, thr; Group III (acidic side chains): asp, glu; Group IV (basic side chains): asn, gln, his, lys, arg; Group V (residues influencing chain orientation): gly, pro; and Group VI (aromatic side chains): trp, tyr, phe. Conservative substitutions involve substitutions between amino acids in the same class. Non-conservative substitutions constitute exchanging a member of one of these classes for a member of another.

[0034] Therapeutic agents of the invention are typically substantially pure from undesired contaminant. This means that an agent is typically at least about 50% w/w (weight/weight) purity, as well as being substantially free from interfering proteins and contaminants. Sometimes the agents are at least about 80% w/w and, more preferably at least 90 or about

95% w/w purity. However, using conventional protein purification techniques, homogeneous peptides of at least 99% w/w can be obtained.

[0035] The term "antibody" or "immunoglobulin" is used to include intact antibodies and binding fragments thereof. Typically, fragments compete with the intact antibody from which they were derived for specific binding to an antigen fragment including separate heavy chains, light chains Fab, Fab' F(ab')₂, Fabc, and Fv. Fragments are produced by recombinant DNA techniques, or by enzymatic or chemical separation of intact immunoglobulins. The term "antibody" also includes one or more immunoglobulin chains that are chemically conjugated to, or expressed as, fusion proteins with other proteins. The term "antibody" also includes bispecific antibody. A bispecific or bifunctional antibody is an artificial hybrid antibody having two different heavy/light chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of methods including fusion of hybridomas or linking of Fab' fragments. See, e.g., Songsivilai & Lachmann, Clin. Exp. Immunol. 79:315-321 (1990); Kostelny et al., J. Immunol. 148, 1547-1553 (1992).

[0036] The term "adjuvant" refers to a compound that when administered in conjunction with an antigen augments the immune response to the antigen, but when administered alone does not generate an immune response to the antigen. Adjuvants can augment an immune response by several mechanisms including lymphocyte recruitment, stimulation of B and/or T cells, and stimulation of macrophages.

[0037] The term "patient" includes human and other mammalian subjects that receive either prophylactic or therapeutic treatment.

[0038] Competition between antibodies is determined by an assay in which the immunoglobulin under test inhibits specific binding of a reference antibody to a common antigen, such as alpha-synuclein. Numerous types of competitive binding assays are known, for example: solid phase direct or indirect radioimmunoassay (RIA), solid phase direct or indirect enzyme immunoassay (EIA), sandwich competition assay (see Stahl et al., Methods in Enzymology 9:242-253 (1983)); solid phase direct biotin-avidin EIA (see Kirkland et al., J. Immunol. 137:3614-3619 (1986)); solid phase direct labeled assay, solid phase direct labeled sandwich assay (see Harlow and Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Press (1988)); solid phase direct label RIA using 1-125 label (see Morel et al., Molec. Immunol. 25(1):7-15 (1988)); solid phase direct biotin-avidin EIA (Cheung et al., Virology 176:546-552 (1990)); and direct labeled RIA (Moldenhauer et al., Scand. J. Immunol. 32:77-82 (1990)). Typically, such an assay involves the use of purified antigen bound to a solid surface or cells bearing either of these, an unlabelled test immunoglobulin and a labeled reference immunoglobulin. Competitive inhibition is measured by determining the amount of label bound to the solid surface or cells in the presence of the test immunoglobulin. Usually the test immunoglobulin is present in excess. Antibodies identified by competition assay (competing antibodies) include antibodies binding to the same epitope as the reference antibody and antibodies binding to an adjacent epitope sufficiently proximal to the epitope bound by the reference antibody for steric hindrance to occur. Usually, when a competing antibody is present in excess, it will inhibit specific binding of a reference antibody to a common antigen by at least 50 or 75%.

[0039] Epitope co-ordinates are approximate (± 2 amino acids). Not every amino acid within an epitope is necessarily required for binding.

[0040] Compositions or methods "comprising" one or more recited elements may include other elements not specifically recited. For example, a composition that comprises alpha-synuclein peptide encompasses both an isolated alpha-synuclein peptide and alpha-synuclein peptide as a component of a larger polypeptide sequence.

[0041] Unless otherwise apparent from the context, each embodiment, element, step or feature of the invention can be used in combination with any other.

DETAILED DESCRIPTION OF THE INVENTION

I. General

[0042] The invention is premised in part on the identification of novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tryptic buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.

[0043] The invention provides several methods for screening agents for activity useful in treating LBDs. Some methods identify agents that inhibit the cleavage reaction that generates the novel fragments of the invention. Other methods identify agents that inhibit aggregation of the products of the cleavage reaction. Such inhibitors are useful for treatment of LBD's. Inhibitors of the cleavage reaction are also useful for affinity purification of the protease responsible for the cleavage reaction.

[0044] Also described herein are transgenic animal models and cells expressing fragments of alpha-synuclein as described above. The transgenic animal models and cells are disposed to develop characteristics of Lewy body disease, including Lewy bodies containing aggregations of the fragments. The animal models and cells can be used in the screening methods described above.

[0045] Further provided are end-specific antibodies that specifically bind to fragments of alpha-synuclein without specifically binding to intact alpha-synuclein per se. These antibodies are useful for in vivo imaging of alpha-synuclein aggregations and also in methods of treatment. The novel alpha-synuclein fragments can also be used in methods of treatment, optionally, in combination with an adjuvant.

II. Alpha-synuclein fragments

[0046] Human alpha-synuclein is a peptide of 140 amino acids having the following amino acid sequence:

MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGVVH
 GVATVAEKTQ EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFKVKKDQL
 GKNEEGAPQE GILEDMPVDP DNEAYEMPSE EGYQDYEPEA
 (SEQ ID NO:1)

(Ueda et al., Proc. Natl. Acad. Sci. USA (1993) 90:11282-6).; GenBank accession number: P37840). The protein has three recognized domains, a KTK repeat domain covering amino acids 1-61, a NAC (Non-amyloid component) domain running from about amino acids 60-95, and a C-terminal acidic domain running from about amino acid 98 to 140.

[0047] Some novel fragments described herein have C-terminal truncations of at least ten contiguous amino acids, preferably at least 15 contiguous amino acids, and optionally at up to 20, 22, 23 or 25 amino acids. The fragments include all or substantially all (i.e., at least 100 contiguous residues from alpha-synuclein other than the deletion). Some fragments also have relatively short truncations at the N-terminus of up to 20 amino acids, such as deletions of residues 1-4, 1-6, 1-10 and 1-12. Some fragments have N-terminal deletions of residues 1-23, 1-38 or 1-45. Preferred fragments of the disclosure are SN1-118, SN1-119, SN1-120, SN1-121, SN1-122, SN1-123, SN1-124, SN1-125, SN1-126, SN1-127, SN1-128, SN 1-129 and SN1-130. Particularly preferred fragments of the disclosure are SN1-119, SN1-120, SN1-121, SN1-122, SN1-123, SN 1-124 and SN 1-125. An especially preferred fragment is SN1-119. The cleavage reaction preferably occurs at a peptide bond between amino acid residues 118 and 126, e.g., between residue 119 and 120. Other fragments of the disclosure include N-terminal fragments of alpha-synuclein of about 6 to 7 kDa (as determined by SDS electrophoresis) or 50-80 amino acids. Other fragments of the disclosure include N-terminal fragments of alpha-synuclein that are free of 1-10 amino acids from the C-terminus of intact alpha-synuclein, i.e., SN 1-X, wherein X is 130-139. Some fragments are characterized by specific binding to antibodies ELADW43 (free N-terminus) and 5C12 (109-120) and lack of specific binding to 8A5 (free C-terminus), LB509 (115-123) and ELAD47 (118-123). Some fragments are characterized by specific binding to ELADW43 (free N-terminus) and 5C12 (109-120), LB509 (115-123) and ELAD47 (118-123) and lack of specific binding to 8A5 (free C-terminus). Some fragments are characterized by specific binding to ELADW43 (free N-terminus) and 5C12 (109-120), LB509 (115-123) and ELAD47 (118-123) and 8A5 (free C-terminus) and lack of specific binding to ELADW43 (free N-terminus).

[0048] Some fragments or full-length alpha synuclein are phosphorylated or nitrated at the tyrosine residue occupying position 125 of alpha synuclein. Fragments retaining amino acid serine 125 or full-length alpha synuclein can also be phosphorylated at this position. Detection of enhanced phosphorylation or nitration at position 125 or phosphorylation at position 129 in a patient relative to the mean in a population of undiseased individuals is an indication of a Lewy body disease. Detection can be performed using an antibody specific for alpha-synuclein phosphorylated or nitrated at position 125. A level is considered enhanced if greater than the mean plus one standard deviation in a population of undiseased individuals.

[0049] The fragments of the invention are distinct from the non-A β component of Alzheimer's disease amyloid (NAC) previously reported. This fragment consisting of at least 28 amino acids residues (residues 60-87) and optionally 35 amino acid residues (residues 61-95). See Iwai, et al., Biochemistry, 34:10139-10145; Jensen et al., Biochem. J. 310 (Pt 1): 91-94 (1995); GenBank accession number S56746.

[0050] Unless otherwise indicated, reference to alpha-synuclein or its fragments includes the natural human amino acid sequence indicated above, or fragments thereof, as well as analogs including allelic, species and induced variants. Amino acids of analogs are assigned the same numbers as corresponding amino acids in the natural human sequence when the analog and human sequence are maximally aligned. Analogs typically differ from naturally occurring peptides

at one, two or a few positions, often by virtue of conservative substitutions. Some natural allelic variants are genetically associated with hereditary LBD. These variants include A30P and A53T. The A53T variation is associated with enhanced levels of phosphorylation at position 129 of alpha synuclein in an individual having the mutation relative to the norm of phosphorylation in undiseased individuals who lack the mutation. Analogs exhibit at least 80 or 90% sequence identity with natural peptides. Some analogs also include unnatural amino acids or modifications of N or C terminal amino acids at one, two or a few positions. For example, the natural glutamic acid residue can be replaced with iso-aspartic acid. Examples of unnatural amino acids are D, alpha, alpha-disubstituted amino acids, N-alkyl amino acids, lactic acid, 4-hydroxyproline, gamma-carboxyglutamate, epsilon-N,N,N-trimethyllysine, epsilon-N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, omega-N-methylarginine, beta-alanine, ornithine, nor-leucine, norvaline, hydroxyproline, thyroxine, gamma-amino butyric acid, homoserine, citrulline, and isoaspartic acid. Analogs typically specifically bind to a polyclonal antibody population generated against natural human alpha-synuclein. The invention also provides D-peptides, in which D-amino acids can be substituted for corresponding natural L-amino acids of alpha-synuclein at most or all positions.

[0051] Alpha-synuclein, its fragments, and analogs can be synthesized by solid phase peptide synthesis or recombinant expression, or can be obtained from natural sources. Automatic peptide synthesizers are commercially available from numerous suppliers, such as Applied Biosystems, Foster City, California. Recombinant expression can be in bacteria, such as *E. coli*, yeast, insect cells or mammalian cells. Procedures for recombinant expression are described by Sambrook et al., *Molecular Cloning: A Laboratory Manual* (C.S.H.P. Press, NY 2d ed., 1989).

III. Lewy Body Diseases

[0052] Lewy Body Disease (LBD) is characterized by degeneration of the dopaminergic system, motor alterations, cognitive impairment, and formation of Lewy bodies (LBs). (McKeith et al., *Clinical and pathological diagnosis of dementia with Lewy bodies (DLB): Report of the CDLB International Workshop, Neurology* (1996) 47:1113-24). Lewy Bodies are spherical protein deposits found in nerve cells. Their presence in the brain disrupts the brain's normal function interrupting the action of chemical messengers including acetylcholine and dopamine. Lewy Body diseases include Parkinson's disease (including idiopathic Parkinson's disease (PD)), Diffuse Lewy Body Disease (DLBD) also known as Dementia with Lewy Bodies (DLB), Combined Alzheimer's and Parkinson disease and multiple system atrophy (MSA). DLBD shares symptoms of both Alzheimer's and Parkinson's disease. DLBD differs from Parkinson's disease mainly in the location of Lewy Bodies. In DLBD Lewy Bodies form mainly in the cortex. In Parkinson's disease, they form mainly in the substantia nigra. Other Lewy Body diseases include Pure Autonomic Failure, Lewy body dysphagia, Incidental LBD, Inherited LBD (e.g., mutations of the alpha-synuclein gene, PARK3 and PARK4) and Multiple System Atrophy (e.g., Olivopontocerebellar Atrophy, Striatonigral Degeneration and Shy-Drager Syndrome).

IV. Transgenic Animals and Cells

[0053] The invention provides non-human transgenic animals having a genome comprising a transgene comprising a nucleic acid segment encoding a C-terminal truncated form of alpha-synuclein as described above. The transgene is preferably present in all or substantially of the somatic and germline cells of the transgenic animal. The nucleic acid segment encoding the C-terminal truncated form of alpha-synuclein is operably linked to one or more regulatory segments that allow the truncated form of alpha-synuclein to be expressed in neuronal cells of the animal. Promoters such as the rat neuron specific enolase promoter, human beta-actin gene promoter, human platelet derived growth factor B (PDGF-B) chain gene promoter, rat sodium channel gene promoter, mouse myelin basic protein gene promoter, human copper-zinc superoxide dismutase gene promoter, and mammalian POU-domain regulatory gene promoter can be used. The PDGF promoter is particularly suitable. Optionally, an inducible promoter is used. The mouse metallothioneine promoter, which can be regulated by addition of heavy metals such as zinc to the mouse's water or diet, is suitable. Such transgenic animals can be produced by the same general approaches described by (Masliah et al., *Am. J. Pathol.* (1996) 148:201-10 and Feany et al., *Nature* (2000) 404:394-8) for transgenic animals with full-length alpha-synuclein or US 5,811,633 (for transgenic animals with a mutant form of APP). Optionally, transgenic animals bearing a transgene expressing a truncated alpha-synuclein protein can be crossed with other transgenic models of neurodegenerative disease, such as models of Alzheimer's disease. For example, transgenic animals bearing a transgene expressing a truncated alpha-synuclein protein can be crossed with transgenic animals bearing a transgene expressed APP with a FAD mutation as described by e.g., Games et al., *Nature* 373, 523 (1995) McConlogue et al., *US 5,612,486*, Hsiao et al., *Science* 274, 99 (1996); Staufenbiel et al., *Proc. Natl. Acad. Sci. USA* 94, 13287-13292 (1997); Sturchler-Pierrat et al., *Proc. Natl. Acad. Sci. USA* 94, 13287-13292 (1997); Borchelt et al., *Neuron* 19, 939-945 (1997)). The procedure for performing such a cross is described by e.g., Masliah et al., *PNAS USA* 98:12245-12250 (2001), which reports a cross between transgenic mice expressing a full length alpha-synuclein with PDAPP mice as described by Games et al. Transgenic animals of the invention are preferably rodents, such as mice or rats, or insects, such as *Drosophila*.

[0054] The expression of truncated forms of alpha-synuclein in animal models gives rise to animals disposed to develop at least one characteristic of a Lewy Body disease. Such characteristics include increased levels of intracellular deposits of alpha-synuclein, increased formation of Lewy bodies, and impaired cognitive and motor functions relative to normal nontransgenic animals of the same species. Such transgenic animals are useful for screening agents for pharmacological activity in treating Lewy Body disease.

[0055] The disclosure also provides cells transformed with truncated alpha -synuclein which form inclusion bodies containing aggregated truncated alpha-synuclein. The transformed cells are preferably neuronal cells, such as GT1-7 neuronal cells (Hsue et al. Am. J. Pathol. 157:401-410 (2000)), PC12 cells or SY5Y neuroblastoma cells. PEAK cells can also be used. The cells are preferably human cells. A vector comprising a segment encoding a truncated form of alpha-synuclein operably linked to one or more regulatory sequences that ensure expression of the truncated expression is transfected into the cells. Transfected cells can be used to screen agents for activity in clearing alpha-synuclein inclusions.

V. Screening Methods

[0056] The invention provide several screening methods to identify agents having a pharmacological activity useful in treating a LBD. The methods include screens that can be performed in vitro, in cells or transgenic animals, and which test a variety of parameters as an indication of activity. Agents determined to have an activity in these screens can be retested in secondary screens of animal models of LBD or in clinical trials to determine activity against behavioral or other symptoms of these diseases.

1. In vitro

[0057] In vitro assays are performed to test the capacity of an agent to inhibit aggregation of truncated forms of alpha-synuclein. The basis format for analyzing in vitro aggregation of alpha-synuclein, albeit in the context of full-length alpha-synuclein, is described by (Wood, J. Biol. Chem. 274, 19509-19512 (1999)). In the present methods, the assay is performed in the presence of an agent being tested. The rate or extent of aggregation of alpha-synuclein in the presence of an agent is determined and compared with the rate or extent of aggregation of alpha-synuclein in a contemporaneous or historical control in which the agent was omitted. A reduction in the rate or extent of aggregation in the presence of the agent relative to the control indicates that the agent has activity in inhibiting aggregation of truncated forms of alpha-synuclein. This activity is potentially useful in treating or preventing Lewy Body diseases.

2. Cellular Assays

[0058] Some cellular assays are performed on cells transfected with nucleic acids encoding truncated forms of alpha-synuclein as described above, optionally with a hereditary variation, such as Ala30Pro or Ala53Th. Such cells are contacted with an agent under test, and the rate or extent of aggregation of the truncated alpha-synuclein is measured. The rate or extent of aggregation of alpha-synuclein is then compared to that of similarly transfected control cells in the absence of the agent. Aggregation can be monitored by immunohistochemical analysis, light microscopy or by gel analysis. Gel analysis can detect formation of dimers, trimers or higher oligomers as well as inability of synuclein to enter gels due to a high level of oligomerization. A reduction in the rate or extent of aggregation in the presence of the test agent relative to the control indicates the agent has activity has a pharmacological activity in inhibiting aggregation of truncated forms of alpha-synuclein. This activity is potentially useful in treating or preventing Lewy Body diseases.

[0059] Other cellular assays are performed on cells transfected with nucleic acids encoding full-length alpha-synuclein, optionally with a hereditary variation, such as Ala30Pro or Ala53Thr. Such cells are contacted with an agent under test and the rate or extent of formation of truncated forms of alpha-synuclein and/or phosphorylated or nitrated forms of synuclein is/are measured. The presence of these forms can be detected by Western blotting using one or more antibodies to alpha-synuclein. End specific antibodies (*i.e.*, antibodies that bind to a truncated form without binding to full length alpha-synuclein) are particularly useful for this analysis. Collections of antibodies having different epitope specificities can also be used. For example, presence of truncated forms of alpha-synuclein can be shown by presence of bands when blotted with antibodies recognizing an epitope N-terminal of an amino acid segment defined approximately by amino acids 118-125 of intact alpha-synuclein, and , and lack of bands when blotted with an antibody recognizing an epitope C-terminal of this region. The rate or extent of formation of truncated forms of alpha-synuclein and/or phosphorylated or nitrated forms in the presence of agent is compared with that of comparable control cells in the absence of agent. A reduction in the rate or extent of formation of truncated forms of alpha-synuclein in the presence of the test agent relative to the control indicates that the agent has a pharmacological activity that inhibits processing of alpha-synuclein to its truncated forms. This activity is useful for treating or preventing LBD.

3. Transgenic Animal Assays

[0060] Transgenic animals have a transgene expressing a truncated form of alpha-synuclein as described above, optionally with a hereditary variation, such as Ala30Pro or Ala53Th. Such an animal is contacted with an agent under test, and the rate of extent of aggregation of the truncated form of alpha-synuclein is measured compared with that in a contemporaneous or historical control. The control is usually a similar transgenic animal of the same species that has not been exposed to the agent. Aggregation of alpha-synuclein in a transgenic animal can be monitored by Western blotting or immunohistochemistry as described in the examples. Alternatively or additionally, activity of the agent in such transgenic animals can be determined from behavioral characteristics such as motor or cognitive characteristics, as described in the Examples. In such assays, pharmacological activity of the agent is shown by improved motor or cognitive characteristics (*i.e.*, decrease impairment of such characteristics) relative to a comparable control transgenic animal not exposed to the agent.

[0061] Other assays are performed on transgenic animals having a transgene expressing a full-length form of alpha-synuclein, optionally with a hereditary variation, such as Ala30Pro or Ala53Th. Such animals are contacted with an agent under test, and the rate or extent of appearance of truncated forms of alpha-synuclein is detected, optionally with a hereditary variation, such as Ala30Pro or Ala53Th. Such forms can be detected using Western blotting or immunohistochemical analysis using appropriate anti-alpha-synuclein antibodies (as described for the cellular assays). The rate of extent of appearance of truncated forms of alpha-synuclein and/or phosphorylated or nitrated forms is compared with the rate or extent of appearance of such forms in a contemporaneous or historical control constituting a comparable transgenic animal that has not been exposed to the agent. A reduction in the rate or extent of appearance of the truncated forms of alpha-synuclein in the animal exposed to the test agent relative to the control indicates that agent has activity in inhibiting processing of full-length alpha-synuclein to truncated forms.

4. Agents to be Screened

[0062] Agents to be screened include antibodies to alpha-synuclein, peptides of alpha-synuclein, drugs known or suspected to have activity in treating a LBD, natural products, and combinatorial libraries. Preferred peptides of alpha-synuclein are relatively short peptides of 30, 25, 20 10 or fewer amino acid including amino acids 118-125 of alpha-synuclein. Optionally, an amino acid immediately on the N-terminal side of the cleavage site that generates C-terminal truncated forms of alpha-synuclein is replaced with a transition state analog amino acid that forms a nonhydrolyzable bond between the two amino acids flanking the cleavage site, *e.g.*, amino acid 119 of alpha synuclein. Examples of analogs are transition state analogs are statine, hydroxyethelene, hydroxyethelamine, AHPPA, ACHPA, and derivatives thereof. One or more amino acids of a natural alpha-synuclein sequence can also be substituted with other natural amino acids.

[0063] Natural products to be screened can also be obtained from the National Cancer Institute's Natural Product Repository, Bethesda, MD. Random libraries of peptides or other compounds can also be screened for suitability. Combinatorial libraries can be produced for many types of compounds that can be synthesized in a step-by-step fashion. Such compounds include polypeptides, beta-turn mimetics, polysaccharides, phospholipids, hormones, prostaglandins, steroids, aromatic compounds, heterocyclic compounds, benzodiazepines, oligomeric N-substituted glycines and oligo-carbamates. Large combinatorial libraries of the compounds can be constructed by the encoded synthetic libraries (ESL) method described in Affymax, WO 95/12608, Affymax, WO 93/06121, Columbia University, WO 94/08051, Pharmaco-peia, WO 95/35503 and Scripps, WO 95/30642. Peptide libraries can also be generated by phage display methods. See, *e.g.*, Devlin, WO 91/18980. Combinatorial libraries and other compounds can initially be screened for suitability by determining their capacity to bind to alpha-synuclein.

VI. Toxicity Assays

[0064] Analogous strategies to those described in the screening assays can be used to determine whether existing drugs, foods, environmental toxins, and other compounds exert toxic effects via promotion of alpha-synuclein processing, phosphorylation or aggregation. Such assays are performed in the same manner as the screening assays. Toxic activity is indicated by the opposite result to pharmacological activity in the screening assays.

VII. Isolation of Protease

[0065] Processing of full-length alpha-synuclein to the truncated forms of the invention is effected by a protease. The protease can be purified using an inhibitor identified by the screening methods discussed above. A preferred inhibitor is a peptide of alpha-synuclein including residues 117-126 in which a residue N-terminal to the cleavage site has been replaced by a transition state analog. Such an inhibitor is used as an affinity purification reagent to purify the protease

from extracts of brain cells. Such cells can be obtained from cadaver of a normal individual or one who has suffered from a LBD disease. Levels of protease may be elevated in the latter. The protease can be assayed by presenting it with an alpha-synuclein substrate and monitoring formation of cleavage products. The substrate can be, for example, the natural human form of alpha-synuclein described above, a fragment thereof containing residues flanking both sides of the cleavage site, or a mutant form thereof in which the mutation is associated with a hereditary form of LBD. Optionally, the C-terminus of the substrate can be immobilized to the solid phase, and the N-terminus to a label. Cleavage of the substrate releases the label to the liquid phase. The liquid phase can readily be separated from the solid phase, and the amount of label quantified as a measure of proteolytic activity.

VIII. End-specific antibodies

[0066] The disclosure provides end-specific antibodies. Such antibodies specifically bind to a truncated form of alpha-synuclein (at the C-terminus), preferably a form selected of the group consisting of SN1-118, SN1-119, 1-120, 1-121, 1-122, 1-123, 1-124, 1-125 or 1-126 without specifically binding to full-length alpha-synuclein. Such antibodies are useful for in vivo imaging of alpha-synuclein deposits, as therapeutic agents (see below), and for detecting cleavage products resulting from proteolytic cleavage of alpha-synuclein in the screening methods described above. End-specific antibodies are also provided to corresponding C-terminal fragments, e.g., 118-140, 119-140, 120-140, 121-140, 122-140, 123-140, 124-140, 125-140 and 126-140. The end-specific antibodies recognize the N-terminus of these fragments such that they specifically bind to the fragment without specifically binding to full-length alpha synuclein.

[0067] Such antibodies can be generated by immunizing a laboratory animal with alpha-synuclein or a fragment thereof to induce antibodies, and screening the resulting antibodies to identify those having the desired binding specificity. Optionally, immunization can be performed with relatively short peptides of less than 20 amino acids that include the C-terminus of the truncated fragments described herein (e.g., SN 99-118, or SN 110-119). Optionally, such short peptides are linked to a carrier that helps elicit an immune response.

[0068] Optionally, specific binding to a labeled or immobilized truncated fragment can be performed in competition with unlabelled full-length alpha-synuclein. Optionally, large libraries of antibodies can be screened simultaneously using the phage display technique.

[0069] The production of non-human monoclonal antibodies, e.g., murine, guinea pig, primate, rabbit or rat, can be performed as described by Harlow & Lane, *Antibodies, A Laboratory Manual* (CSHP NY, 1988). Complete Freund's adjuvant followed by incomplete adjuvant is preferred for immunization of laboratory animals. Rabbits or guinea pigs are typically used for making polyclonal antibodies. Mice are typically used for making monoclonal antibodies. Binding can be assessed, for example, by Western blot or ELISA. The smallest fragment to show specific binding to the antibody defines the epitope of the antibody. Alternatively, epitope specificity can be determined by a competition assay in which a test and reference antibody compete for binding to alpha-synuclein. If the test and reference antibodies compete, then they bind to the same epitope or epitopes sufficiently proximal that binding of one antibody interferes with binding of the other.

[0070] Chimeric and humanized antibodies have the same or similar binding specificity and affinity as a mouse or other nonhuman antibody that provides the starting material for construction of a chimeric or humanized antibody. Chimeric antibodies are antibodies whose light and heavy chain genes have been constructed, typically by genetic engineering, from immunoglobulin gene segments belonging to different species. For example, the variable (V) segments of the genes from a mouse monoclonal antibody may be joined to human constant (C) segments, such as IgG1 and IgG4. Human isotype IgG1 is preferred. In some methods, the isotype of the antibody is human IgG1. IgM antibodies can also be used in some methods. A typical chimeric antibody is thus a hybrid protein consisting of the V or antigen-binding domain from a mouse antibody and the C or effector domain from a human antibody.

[0071] Humanized antibodies have variable region framework residues substantially from a human antibody (termed an acceptor antibody) and complementarity determining regions substantially from a mouse-antibody, (referred to as the donor immunoglobulin). See, Queen et al., *Proc. Natl. Acad. Sci. USA* 86:10029-10033 (1989), WO 90/07861, US 5,693,762, US 5,693,761, US 5,585,089, US 5,530,101, and Winter, US 5,225,539. The constant region(s), if present, are also substantially or entirely from a human immunoglobulin. The human variable domains are usually chosen from human antibodies whose framework sequences exhibit a high degree of sequence identity with the murine variable region domains from which the CDRs were derived. The heavy and light chain variable region framework residues can be derived from the same or different human antibody sequences. The human antibody sequences can be the sequences of naturally occurring human antibodies or can be consensus sequences of several human antibodies. See Carter et al., WO 92/22653. Certain amino acids from the human variable region framework residues are selected for substitution based on their possible influence on CDR conformation and/or binding to antigen. Investigation of such possible influences is by modeling, examination of the characteristics of the amino acids at particular locations, or empirical observation of the effects of substitution or mutagenesis of particular amino acids.

[0072] Human antibodies against alpha-synuclein are provided by a variety of techniques described below. Some

human antibodies are selected by competitive binding experiments, or otherwise, to have the same epitope specificity as a particular mouse antibody. Techniques for producing human antibodies include the trioma methodology of Oestberg et al., Hybridoma 2:361-367 (1983); Oestberg, US Patent No. 4,634,664; and Engleman et al., US Patent 4,634,666, use of non-human transgenic mammals having transgenes encoding at least a segment of the human immunoglobulin locus as described by, e.g., Lonberg et al., WO93/1222, US 5,877,397, US 5,874,299, US 5,814,318, US 5,789,650, US 5,770,429, US 5,661,016, US 5,633,425, US 5,625,126, US 5,569,825, US 5,545,806, Nature 148, 1547-1553 (1994), Nature Biotechnology 14, 826 (1996), Kucherlapati, WO 91/10741 and phage display methods see, e.g., Dower et al., WO 91/17271 and McCafferty et al., WO 92/01047, US 5,877,218, US 5,871,907, US 5,858,657, US 5,837,242, US 5,733,743 and US 5,565,332.

[0073] The heavy and light chain variable regions of chimeric, humanized, or human antibodies can be linked to at least a portion of a human constant region. The choice of constant region depends, in part, whether antibody-dependent complement and/or cellular mediated toxicity is desired. For example, isotopes IgG1 and IgG3 have complement activity and isotypes IgG2 and IgG4 do not. Choice of isotype can also affect passage of antibody into the brain. Human isotype IgG1 is preferred. Light chain constant regions can be lambda or kappa. Antibodies can be expressed as tetramers containing two light and two heavy chains, as separate heavy chains, light chains, as Fab, Fab' F(ab')₂, and Fv, or as single chain antibodies in which heavy and light chain variable domains are linked through a spacer.

[0074] Monoclonal antibodies specifically binding to an epitope within residues 109-120, or 115-123, of alpha synuclein, or a discontinuous epitope within residues 43-51 and 68-65, or end-specific to the C-terminus of alpha-synuclein are also provided, including humanized, chimeric and human forms thereof. An end-specific antibody to the C-terminus of alpha-synuclein can be recognized by capacity to specifically bind to alpha-synuclein as a free protein without specifically binding to alpha synuclein as a component of a fusion protein when the C-terminus of alpha-synuclein is linked to a second peptide. These antibodies can be screened for therapeutic activity, and if positive results are obtained, can be used in therapeutic methods. The antibodies can also be used in detecting fragments of alpha-synuclein as described above.

IX. Diagnostics

[0075] The disclosure provides methods of *in vivo* imaging LBs in a patient. Such methods are useful to diagnose or confirm diagnosis of a Lewy Body disease of PD or susceptibility thereto. For example, the methods can be used on a patient presenting with symptoms of dementia. If the patient has LBs, then the patient is likely suffering from a Lewy Body disease. The methods can also be used on asymptomatic patients. Presence of abnormal deposits of amyloid indicates susceptibility to future symptomatic disease. The methods are also useful for monitoring disease progression and/or response to treatment in patients who have been previously diagnosed with a Lewy Body disease.

[0076] The methods work by administering an end-specific antibody as described above that binds to alpha-synuclein in the patient and then detecting the antibody after it has bound. If desired, a clearing response can be avoided by using antibody fragments lacking a full length constant region, such as Fabs. In some methods, the same antibody can serve as both a treatment and diagnostic reagent.

[0077] Diagnostic reagents can be administered by intravenous injection into the body of the patient, or directly into the brain by intracranial injection or by drilling a hole through the skull. The dosage of reagent should be within the same ranges as for treatment methods. Typically, the reagent is labeled, although in some methods, the primary reagent with affinity for alpha-synuclein is unlabelled and a secondary labeling agent is used to bind to the primary reagent. The choice of label depends on the means of detection. For example, a fluorescent label is suitable for optical detection. Use of paramagnetic labels is suitable for tomographic detection without surgical intervention. Radioactive labels can also be detected using PET or SPECT.

[0078] Diagnosis is performed by comparing the number, size and/or intensity of labeled loci to corresponding base line values. The base line values can represent the mean levels in a population of undiseased individuals. Base line values can also represent previous levels determined in the same patient. For example, base line values can be determined in a patient before beginning treatment, and measured values thereafter compared with the base line values. A decrease in values relative to base line signals a positive response to treatment.

[0079] End-specific antibodies are also useful to determine whether truncated forms of alpha-synuclein are present in cerebrospinal fluid or other body tissues or fluids. Presence of such forms at significantly greater levels (*i.e.*, greater than mean plus one standard deviation) in a patient relative to the normal level in a population of undiseased individuals is indicative of presence or susceptibility to a LBD.

X. Methods of Treatment

[0080] The description also provides several methods of preventing or treating Lewy Body disease in patients suffering from or at risk of such disease. Therapeutic agents include the truncated forms of alpha-synuclein described above, and

fragments thereof effective to induce antibodies, end-specific antibodies as described above, and inhibitors of aggregation of truncated fragments of alpha-synuclein or proteolytic processing of alpha-synuclein as described above. General approaches for administering agents to patients suffering or at risk of LBD are described in copending application USSN 60/423,012 filed November 1, 2002, and PCT US00/15239 filed June 1, 2000, and PCT/US03/34527, filed October 31, 2003.

[0081] Patients amenable to treatment include individuals at risk of disease of a LBD but not showing symptoms, as well as patients presently showing symptoms. Therefore, the present methods can be administered prophylactically to individuals who have a known genetic risk of a LBD. Such individuals include those having relatives who have experienced this disease, and those whose risk is determined by analysis of genetic or biochemical markers. Genetic markers of risk toward PD include mutations in the alpha-synuclein or Parkin, UCHL1, and CYP2D6 genes; particularly mutations at positions 30 and 53 of the alpha-synuclein gene. Individuals presently suffering from Parkinson's disease can be recognized from its clinical manifestations including resting tremor, muscular rigidity, bradykinesia and postural instability.

[0082] In some methods, the patient is free of clinical symptoms or risk factors any amyloidogenic disease other than one characterized by Lewy bodies. In some methods, the patient is free of clinical symptoms or risk factors of any disease characterized by extracellular amyloid deposits. In some methods, the patient is free of diseases characterized by amyloid deposits of A β peptide. In some methods, the patient is free of clinical symptoms and risk factors of Alzheimer's disease. In some methods, the patient has concurrent Alzheimer's disease and a disease characterized by Lewy bodies. In some methods, the patient has concurrent Alzheimer's and Parkinson's disease.

[0083] In asymptomatic patients, treatment can begin at any age (e.g., 10, 20, 30). Usually, however, it is not necessary to begin treatment until a patient reaches 40, 50, 60 or 70. Treatment typically entails multiple dosages over a period of time. Treatment can be monitored by assaying antibody, or activated T-cell or B-cell responses to a therapeutic agent (e.g., a truncated form of alpha-synuclein peptide) over time. If the response falls, a booster dosage is indicated.

[0084] In prophylactic applications, pharmaceutical compositions or medicaments are administered to a patient susceptible to, or otherwise at risk of a LBD in regime comprising an amount and frequency of administration of the composition or medicament sufficient to eliminate or reduce the risk, lessen the severity, or delay the outset of the disease, including physiological, biochemical, histologic and/or behavioral symptoms of the disease, its complications and intermediate pathological phenotypes presenting during development of the disease. In therapeutic applications, compositions or medicaments are administered to a patient suspected of, or already suffering from such a disease in a regime comprising an amount and frequency of administration of the composition sufficient to cure, or at least partially arrest, the symptoms of the disease (physiological, biochemical, histologic and/or behavioral), including its complications and intermediate pathological phenotypes in development of the disease. An amount adequate to accomplish therapeutic or prophylactic treatment is defined as a therapeutically- or prophylactically-effective dose. A combination of amount and dosage frequency adequate to accomplish therapeutic or prophylactic treatment is defined as a therapeutically or prophylactically-effective regime. In both prophylactic and therapeutic regimes, agents are usually administered in several dosages until a sufficient immune response has been achieved. Typically, the immune response is monitored and repeated dosages are given if the immune response starts to wane.

[0085] In some methods, administration of an agent results in reduction of intracellular levels of aggregated alpha-synuclein. In some methods, administration of the agent results in a reduction in levels of C-terminal truncated forms of alpha-synuclein. In some methods, administration of an agent results in improvement in a clinical symptom of a LBD, such as motor or cognitive function in the case of Parkinson's disease. In some methods, reduction in intracellular levels of aggregated alpha-synuclein or improvement in a clinical symptom of disease is monitored at intervals after administration of an agent.

[0086] Effective doses of the compositions of the present invention, for the treatment of the above described conditions vary depending upon many different factors, including means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic. Usually, the patient is a human but nonhuman mammals including transgenic mammals can also be treated. Treatment dosages need to be titrated to optimize safety and efficacy.

[0087] In some methods, the agent is a truncated fragment of alpha-synuclein or a fragment thereof capable of inducing antibodies to alpha-synuclein. The amount of such a fragment depends on whether adjuvant is also administered, with higher dosages being required in the absence of adjuvant. The amount of a fragment for administration sometimes varies from 1-500 μ g per patient and more usually from 5-500 μ g per injection for human administration. Occasionally, a higher dose of 1-2 mg per injection is used. Typically about 10, 20, 50 or 100 μ g is used for each human injection. The mass of fragment also depends on the mass ratio of immunogenic epitope within the fragment to the mass of fragment as a whole. Typically, 10^{-3} to 10^{-5} micro moles of immunogenic epitope are used for microgram of fragment. The timing of injections can vary significantly from once a day, to once a year, to once a decade. On any given day that a dosage of immunogen is given, the dosage is greater than 1 μ g/patient and usually greater than 10 μ g/patient if adjuvant is also administered, and greater than 10 μ g/patient and usually greater than 100 μ g/patient in the absence of adjuvant. A typical regimen consists of an immunization followed by booster injections at time intervals, such as 6 week

intervals. Another regimen consists of an immunization followed by booster injections 1, 2 and 12 months later. Another regimen entails an injection every two months for life. Alternatively, booster injections can be on an irregular basis as indicated by monitoring of immune response.

[0088] Truncated fragments of alpha-synuclein can also be administered in the form of nucleic acids encoding the fragments operably linked to one or more regulatory elements to ensure expression of the truncated fragment of alpha-synuclein. Doses for nucleic acids encoding immunogens range from about 10 ng to 1 g, 100 ng to 100 mg, 1 µg to 10 mg, or 30-300 µg DNA per patient. Doses for infectious viral vectors vary from 10-100, or more, virions per dose.

[0089] Some methods involve passive immunization with an end-specific antibody. In such methods, the dosage ranges from about 0.0001 to 100 mg/kg, and more usually 0.01 to 5 mg/kg, of the host body weight. For example dosages can be 1 mg/kg body weight or 10 mg/kg body weight or within the range of 1-10 mg/kg or, in other words, 70 mg or 700 mg or within the range of 70-700 mg, respectively, for a 70 kg patient. An exemplary treatment regime entails administration once per every two weeks or once a month or once every 3 to 6 months. In some methods, two or more monoclonal antibodies with different binding specificities are administered simultaneously, in which case the dosage of each antibody administered falls within the ranges indicated. Antibody is usually administered on multiple occasions. Intervals between single dosages can be weekly, monthly or yearly. Intervals can also be irregular as indicated by measuring blood levels of antibody to alpha-synuclein in the patient. In some methods, dosage is adjusted to achieve a plasma antibody concentration of 1-1000 µg/ml and in some methods 25-300 µg/ml. Alternatively, antibody can be administered as a sustained release formulation, in which case less frequent administration is required. Dosage and frequency vary depending on the half-life of the antibody in the patient. In general, human antibodies show the longest half life, followed by humanized antibodies, chimeric antibodies, and nonhuman antibodies. The dosage and frequency of administration can vary depending on whether the treatment is prophylactic or therapeutic. In prophylactic applications, a relatively low dosage is administered at relatively infrequent intervals over a long period of time. Some patients continue to receive treatment for the rest of their lives. In therapeutic applications, a relatively high dosage at relatively short intervals is sometimes required until progression of the disease is reduced or terminated, and preferably until the patient shows partial or complete amelioration of symptoms of disease. Thereafter, the patient can be administered a prophylactic regime.

[0090] Therapeutic agents can be administered by parenteral, topical, intravenous, oral, subcutaneous, intraarterial, intracranial, intrathecal, intraperitoneal, intranasal or intramuscular means for prophylactic and/or therapeutic treatment. The most typical route of administration of an immunogenic agent is subcutaneous although other routes can be equally effective. The next most common route is intramuscular injection. This type of injection is most typically performed in the arm or leg muscles. In some methods, agents are injected directly into a particular tissue where deposits have accumulated, for example intracranial injection. Intramuscular injection or intravenous infusion is preferred for administration of antibody. In some methods, particular therapeutic antibodies are injected directly into the cranium. In some methods, antibodies are administered as a sustained release composition or device, such as a Medipad™ device. Small molecules that act by inhibiting protease processing of alpha-synuclein can be administered intravenously if the small molecules pass through the blood brain barrier sufficiently for therapeutic or prophylactic efficacy or directly into the cranium otherwise.

[0091] Agents of the invention can optionally be administered in combination with other agents that are at least partly effective in treatment of LBD. Agents of the invention can also be administered in conjunction with other agents that increase passage of the agents of the invention across the blood-brain barrier.

[0092] Immunogenic agents are sometimes administered in combination with an adjuvant. A variety of adjuvants can be used in combination with a peptide, such as alpha-synuclein, to elicit an immune response. Preferred adjuvants augment the intrinsic response to an immunogen without causing conformational changes in the immunogen that affect the qualitative form of the response. Preferred adjuvants include aluminum hydroxide and aluminum phosphate, 3 De-O-acylated monophosphoryl lipid A (MPL™) (see GB 2220211 (RIBI ImmunoChem Research Inc., Hamilton, Montana, now part of Corixa). Stimulon™ QS-21 is a triterpene glycoside or saponin isolated from the bark of the Quillaja Saponaria Molina tree found in South America (see Kensil et al., in Vaccine Design: The Subunit and Adjuvant Approach (eds. Powell & Newman, Plenum Press, NY, 1995); US Patent No. 5,057,540), (Aquila BioPharmaceuticals, Framingham, MA). Other adjuvants are oil in water emulsions (such as squalene or peanut oil), optionally in combination with immune stimulants, such as monophosphoryl lipid A (see Stoute et al., N. Engl. J. Med. 336, 86-91 (1997)), pluronic polymers, and killed mycobacteria. Another adjuvant is CpG (WO 98/40100). Alternatively, alpha-synuclein can be coupled to an adjuvant. However, such coupling should not substantially change the conformation of alpha-synuclein so as to affect the nature of the immune response thereto. Adjuvants can be administered as a component of a therapeutic composition with an active agent or can be administered separately, before, concurrently with, or after administration of the therapeutic agent.

[0093] A preferred class of adjuvants is aluminum salts (alum), such as alum hydroxide, alum phosphate, alum sulfate. Such adjuvants can be used with or without other specific immunostimulating agents such as MPL or 3-DMP, QS-21, polymeric or monomeric amino acids such as polyglutamic acid or polylysine. Another class of adjuvants is oil-in-water emulsion formulations. Such adjuvants can be used with or without other specific immunostimulating agents such as

muramyl peptides (e.g., N-acetylmuramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), N-acetylglucosaminyl-N-acetylmuramyl-L-Al-D-isoglu-L-Ala-dipalmitoxy propylamide (DTP-DPP) theramide™), or other bacterial cell wall components. Oil-in-water emulsions include (a) MF59 (WO 90/14837), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE) formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton MA), (b) SAF, containing 10% Squalene, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP, either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) Ribi™ adjuvant system (RAS), (Ribi ImmunoChem, Hamilton, MT) containing 2% squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphoryllipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (Detox™).

[0094] Another class of preferred adjuvants is saponin adjuvants, such as Stimulon™ (QS-21, Aquila, Framingham, MA) or particles generated therefrom such as ISCOMs (immunostimulating complexes) and ISCOMATRIX. Other adjuvants include RC-529, GM-CSF and Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA). Other adjuvants include cytokines, such as interleukins (e.g., IL-1, IL-2, IL-4, IL-6, IL-12, IL13, and IL-15), macrophage colony stimulating factor (M-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), and tumor necrosis factor (TNF). Another class of adjuvants is glycolipid analogues including N-glycosylamides, N-glycosylureas and N-glycosylcarbamates, each of which is substituted in the sugar residue by an amino acid, as immuno-modulators or adjuvants (see US Pat. No. 4,855,283). Heat shock proteins, e.g., HSP70 and HSP90, may also be used as adjuvants.

[0095] An adjuvant can be administered with an alpha-synuclein fragment as a single composition, or can be administered before, concurrent with or after administration of the alpha-synuclein fragment. The alpha-synuclein fragment and adjuvant can be packaged and supplied in the same vial or can be packaged in separate vials and mixed before use. The alpha-synuclein fragment and adjuvant are typically packaged with a label indicating the intended therapeutic application. If the alpha-synuclein fragment and adjuvant are packaged separately, the packaging typically includes instructions for mixing before use. The choice of an adjuvant and/or carrier depends on the stability of the immunogenic formulation containing the adjuvant, the route of administration, the dosing schedule, the efficacy of the adjuvant for the species being vaccinated, and, in humans, a pharmaceutically acceptable adjuvant is one that has been approved or is approvable for human administration by pertinent regulatory bodies. For example, Complete Freund's adjuvant is not suitable for human administration. Alum, MPL and QS-21 are preferred. Optionally, two or more different adjuvants can be used simultaneously. Preferred combinations include alum with MPL, alum with QS-21, MPL with QS-21, MPL or RC-529 with GM-CSF, and alum, QS-21 and MPL together. Also, Incomplete Freund's adjuvant can be used (Chang et al., *Advanced Drug Delivery Reviews* 32, 173-186 (1998)), optionally in combination with any of alum, QS-21, and MPL and all combinations thereof.

[0096] Agents of the invention are often administered as pharmaceutical compositions comprising an active therapeutic agent, *i.e.*, and a variety of other pharmaceutically acceptable components. See Remington's Pharmaceutical Science (15th ed., Mack Publishing Company, Easton, Pennsylvania, 1980). The preferred form depends on the intended mode of administration and therapeutic application. The compositions can also include, depending on the formulation desired, pharmaceutically-acceptable, non-toxic carriers or diluents, which are defined as vehicles commonly used to formulate pharmaceutical compositions for animal or human administration. The diluent is selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, physiological phosphate-buffered saline, Ringer's solutions, dextrose solution, and Hank's solution. In addition, the pharmaceutical composition or formulation may also include other carriers, adjuvants, or nontoxic, nontherapeutic, nonimmunogenic stabilizers and the like.

[0097] Pharmaceutical compositions can also include large, slowly metabolized macromolecules such as proteins, polysaccharides such as chitosan, polylactic acids, polyglycolic acids and copolymers (such as latex functionalized Sepharose™), agarose, cellulose, and the like), polymeric amino acids, amino acid copolymers, and lipid aggregates (such as oil droplets or liposomes). Additionally, these carriers can function as immunostimulating agents (*i.e.*, adjuvants).

[0098] For parenteral administration, agents of the invention can be administered as injectable dosages of a solution or suspension of the substance in a physiologically acceptable diluent with a pharmaceutical carrier that can be a sterile liquid such as water oils, saline, glycerol, or ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, surfactants, pH buffering substances and the like can be present in compositions. Other components of pharmaceutical compositions are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, and mineral oil. In general, glycols such as propylene glycol or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions. Antibodies can be administered in the form of a depot injection or implant preparation which can be formulated in such a manner as to permit a sustained release of the active ingredient. An exemplary composition comprises monoclonal antibody at 5 mg/mL, formulated in aqueous buffer consisting of 50 mM L-histidine, 150 mM NaCl, adjusted to pH 6.0 with HCl. Compositions for parenteral administration are typically substantially sterile, substantially isotonic and manufactured under GMP conditions of the FDA or similar body.

[0099] Typically, compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms

suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared. The preparation also can be emulsified or encapsulated in liposomes or micro particles such as polylactide, polyglycolide, or copolymer for enhanced adjuvant effect, as discussed above (see Langer, Science 249, 1527 (1990) and Hanes, Advanced Drug Delivery Reviews 28, 97-119 (1997)). The agents of this invention can be administered in the form of a depot injection or implant

preparation which can be formulated in such a manner as to permit a sustained or pulsatile release of the active ingredient. **[0100]** Additional formulations suitable for other modes of administration include oral, intranasal, and pulmonary formulations, suppositories, and transdermal applications. For suppositories, binders and carriers include, for example, polyalkylene glycols or triglycerides; such suppositories can be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1%-2%. Oral formulations include excipients, such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, and magnesium carbonate. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10%-95% of active ingredient, preferably 25%-70%.

[0101] Topical application can result in transdermal or intradermal delivery. Topical administration can be facilitated by co-administration of the agent with cholera toxin or detoxified derivatives or subunits thereof or other similar bacterial toxins (See Glenn et al., Nature 391, 851 (1998)). Co-administration can be achieved by using the components as a mixture or as linked molecules obtained by chemical crosslinking or expression as a fusion protein. Alternatively, transdermal delivery can be achieved using a skin path or using transferosomes (Paul et al., Eur. J. Immunol. 25, 3521-24 (1995); Cevc et al., Biochem. Biophys. Acta 1368, 201-15 (1998)).

Examples

1. Detecting truncated forms of alpha-synuclein in a transgenic animal

[0102] Transgenic mice having a nucleic acid encoding intact alpha-synuclein operably linked to a PDGF promoter were analyzed at 6 weeks, 3 months and 12 months old. The animals were euthanized and the cortex and hippocampus tissue from four mice (2 male/2 female) was pooled. The tissue was homogenized in TBS (250 mM NaCl), and spun at 150,000 x g for 15 minutes. The pellet was then extracted with 1% Triton-X 100 for 30 min at 4 degrees and spun as before. The resulting pellet was then extracted with 1% SDS for 30 min at 25 degrees and spun as before. Finally, the pellet was extracted with 8 M Urea/ 1% SDS. This procedure resulted in four extracts which will be referred to as Tris, Triton, SDS, and Urea extracts in the description that follows.

[0103] Figs. 1A and B show a Western blot of extracts from a transgenic mouse and a matched control with antibody ELADW-47. This antibody is a polyclonal that binds to an epitope within Sun115-122 (but does not necessarily require each amino acid for some binding to occur). The antibody preferentially binds the human form of alpha-synuclein but also binds the mouse form to a lesser extent. Figs. 1A and B shows an alpha-synuclein band at 14 kDa for both the control mouse and the transgenic mouse. The band is stronger for the transgenic mouse than the control. For the different extracts, the band is most intense in the Triton extract. This extract solubilizes membrane bound alpha-synuclein and possibly Lewy body-like inclusions. The Tris and particularly the Triton extractions of the transgenic mouse (but not the control) show a band at about 12 kDa in a trycine buffer. This is a truncated form of alpha-synuclein. The molecular weight of the band corresponds to a length of about 115-120 amino acids.

[0104] Fig. 2 shows a Western blot with the same antibody as Fig. 1 to compare the level of the truncated form of alpha-synuclein in mice of 3 months and 12 months in age. The Figure shows that the truncated form appears more strongly in the 3 month old mice. Again, the truncated band does not appear in the control mice. The more intense appearance of the truncated form of alpha-synuclein early in development of the transgenic mice indicates that the truncated form of alpha-synuclein has a role early in the pathogenesis of Lewy Body disease.

[0105] Figs. 3A and B show a Western blot with a different antibody termed 12C1 (binds epitope at amino acids 43-51 and 58-65, monoclonal, IgG1 k). This antibody binds equally to mouse and human forms of alpha-synuclein at an epitope including amino acids 43-51 and 58-65. Fig. 3 shows the truncated band of 12 kDa in the Triton extract of the transgenic mice. The same band appears much more faintly in the Triton extract of the control mice. Thus, processing of alpha-synuclein to a truncated form occurs in both normal mice and transgenic mice, but more strongly in the latter. The greater extent of processing in the transgenic mice may be due to processing of the human alpha-synuclein directly, or may be due to the presence of human alpha-synuclein driving mouse alpha-synuclein down a path that is used to a lesser extent in nontransgenic mice.

[0106] Fig. 4 shows a further Western blot using the same antibody as Fig. 3. This gel shows two additional bands of molecular weights approximately 6 or 7 kDa. The 7 kDa band appears more strongly in the transgenic mice than control mice. The 6 kDa band appears only in the transgenic mouse, and then only in the 3 mo sample. The 6 or 7 kDa bands are indicative of shorter N-terminal fragments of alpha-synuclein of length about 50-80 amino acids.

[0107] Figs. 5A, B, C, D, E shows Western blots with four different antibodies and epitope maps of the binding sites of the antibodies. ELADW-44 is a polyclonal that binds only to the human form of alpha-synuclein (*i.e.*, not the mouse

form) It binds to at epitope at amino acids 98-019. ELADW-47 is a polyclonal that binds preferentially to the human form but also binds the mouse form. It binds to an epitope at amino acids 115-122. ELADW-48 is a polyclonal that binds the human and mouse forms equally. It binds to an epitope between amino acids 131 and 140. 8A5 is a monoclonal that binds to the human and mouse forms equally. It binds to the C-terminus of alpha-synuclein. Figs. 5A-E shows that of these four antibodies, only ELADW-47 generated a 12 kDa band indicative of a truncated form of alpha-synuclein. The result that ELADW48 did not give rise to this band is of assistance in mapping the site of cleavage. Because ELAD-47 did bind and ELAD-48 did not the site of cleavage is bordered by the N-terminal end of the ELADW-47 epitope and the C-terminal amino acid of the ELADW48 epitope. Further, because some amino acids from the ELADW-47 epitope must be present to allow binding and some of the ELADW-48 epitope must be absent to prevent binding, the cleavage site is further confined to a region approximately within amino acids 118-135. When this data is considered with the size of the truncated fragment (about 115-120 amino acids) then the probable site of cleavage is around amino acids 118-121. The lack of binding by the C-terminal antibody 8A5 is consistent with this cleavage site. The lack of binding by the antibody ELADW-44, however, requires further comment. The lack of cleavage can be explained if a truncated form of human alpha-synuclein resulting from cleavage adapts a different conformation to intact alpha-synuclein preventing binding of ELADW-44. Alternatively, the truncated form of alpha-synuclein present in transgenic mice to a greater extent than in normal mice represent a form of mouse alpha-synuclein. In this case, the greater amount of the truncated form in the transgenic mouse would be due to the presence of the human alpha-synuclein driving more of the mouse alpha-synuclein down a processing path that leads to truncated alpha-synuclein relative to the situation in a control mouse.

2. Detecting Truncated Forms of Alpha-Synuclein in the Brain of a Patient with DLBD

[0108] This examples compares alpha-synuclein species in LBs to those in the remaining soluble and particulate protein fractions of a DLBD brain. LBs and soluble protein were prepared from the cortex of a single DLBD patient (see Jensen et al., J. Biol. Chem. 275 21500-21507 (2000)). Tissue was homogenized in Tris/sucrose (0.32 mM)/EDTA (5mM) and protease inhibitors buffer. The homogenate was spun at 1000g. The supernatant was subjected to a further spin at 150 kg. The supernatant from this spin was used to prepare a Tris soluble fraction of proteins. The pellet from the 1000g was resuspended and used to prepare a Lewy body fraction. Lewy bodies were purified by immunoprecipitation on magnetic beads bearing anti-synuclein antibodies. The precipitate was then extracted with 7 M Urea 2 M Thiourea/4% CHAPS. The bound form was reextracted with Urea/Thiourea/CHAPS. The extracts from this step and the previous extraction were then pooled and analyzed by 2D PAGE and immunoblot. The bound form was subject to further extraction with 90% formic acid. The extract was stored diluted to 9% formic acid. The extract was then analyzed by SDS PAGE and RP-HPLC.

[0109] Synuclein species were resolved on 2-D gels and detected on Western blots. Multiple alpha-synuclein species, including phosphorylated and truncated species, were present in both LBs and the soluble brain fraction. The predominant truncations were in the C-terminal region of alpha-synuclein at approximately amino acids 120-125. An additional larger fragment cleaved close to the C-terminus was also observed. No beta or gamma-synuclein was detected in the LBs despite being found in the soluble protein fraction. The alpha-synuclein in the LB preparation differed from that in the soluble fraction in that it had additional C-terminal cleavages, and that overall the truncated alpha-synuclein species were enriched in the LBs relative to the soluble protein fraction. In addition, multiple alpha-synuclein species of higher molecular mass, approximately 25-35 kDa, were detected only in the LB preparation. The C-terminally truncated fragments are of the same size as those observed in the transgenic mouse model of Example 1 indicating a role in disease pathogenesis.

[0110] Figs. 6A, B, C shows Tris extracts probed with different antibodies, subject to 2-D gel electrophoresis and subjected to Western blotting. The dark spots present toward the left of the charts represent full-length alpha-synuclein. The most notable feature is four spots in the Syn-1 chart that are absent in the 8A5 chart. These four spots represent truncated forms of alpha-synuclein that are unable to bind the 8A5 antibody because of the lack of a C-terminal amino acid. These truncations correspond approximately to forms of SN between 1-120 and 1-125. Several additional spots are seen underneath and adjacent to the full length alpha-synuclein spots. The spots underneath the full length spots probably represent minor truncations from the C-terminus (i.e., synuclein 1-X, wherein X is 130-139). The spot adjacent the full-length spots but to the right represent a minor deletion from the N-terminus (due to lack of this spot in the blot with ELADW43).

[0111] Figs. 7A, B, C, D shows blots with additional antibodies. The four spots are present with 5C12 (109-120). Two of the spots are present with ELADW47 (118-123) and the spots are absent with LB509 (115-123). The spots may differ from each other both in molecular weight and in the presence or absence of posttranslational modification, such as nitration or phosphorylation. These results fix the sites of cleavage to within about amino acids 120-125 of alpha-synuclein. Also notable are several spots running slight below (lower molecular weight) or to the right (higher pH) than the unmodified synuclein spots. These likely may represent forms of synuclein that have undergone a small extent of truncation and/or different posttranslational modification relative to the main spots.

[0112] Fig. 8 summarizes the sites of cleavage relative to the epitopes bound by antibodies used in the Western blotting.

[0113] Figs. 9A, B compare the Tris soluble proteins with proteins extracted from Lewy bodies by 2D electrophoresis and Western blotting. The Tris blot on the left shows four spots at lower molecular weight representing truncated forms of alpha-synuclein (probably in the 1-120 to 1-125 amino acid range). These are of relatively low intensity compared to the spots representative of full length alpha-synuclein. The blot of proteins from Lewy bodies shows more spots representative of truncated forms of alpha synuclein in the 1-120 to 1-125 range. However, these are of greater intensity relative to the spots representative of full length alpha synuclein. Also, apparent are two spots migrating faster than full-length alpha synuclein but slower than the collection of spots at the bottom of the blot. These spots probably represent truncations in the range 1-X wherein X is 130-139 amino acids.

[0114] Figs. 10A, B, C, D show the immunoblots of proteins from Lewy bodies reprobed with various C-terminal antibodies. All spots appear with Syn-1 (91-96) and 5C12 (109-120). With ELADW47, the spot running at the fastest speed and most basic position in the Syn-1 and 5C12 blots is missing. In the LB509 blot, all of the faster moving/more basic spots in the other blots are missing or faint. The absence or reduced intensity of certain spots in the ELADW47 and LB509 blots indicates that these spots represent truncated forms of alpha-synuclein and are consistent with cleavage occurring approximately between amino acids 120 and 125.

3. Detecting Aggregated Alpha-Synuclein in a Transgenic Animal

[0115] Transgenic animals are euthanized and brains are removed for neurochemical and neuropathological analysis. Briefly, the right hemibrain is frozen and homogenized for determinations of aggregated and non-aggregated human alpha-synuclein immunoreactivity by Western blot (Masliah et al., Science (2000) 287:1265). The left hemibrain is fixed in 4% paraformaldehyde, serially sectioned in the vibratome for immunocytochemistry and ultrastructural analysis.

[0116] Brain sections are immunostained with a rabbit polyclonal antibody against human alpha-synuclein (1:500). After an overnight incubation at 4°C, sections are incubated with biotinylated anti-rabbit secondary antibody followed by Avidin D-Horseradish peroxidase (HRP) complex (1:200, ABC Elite, Vector). The reaction is visualized with 0.1% 3,3'-diaminobenzidine tetrahydrochloride (DAB) in 50mM Tris-HCl (pH 7.4) with 0.001 % H₂O₂ and sections are then mounted on slides under Entellan. Levels of immunoreactivity are semi quantitatively assessed by optical densitometry using the Quantimet 570C. These sections are also studied by image analysis to determine the numbers of alpha-synuclein immunoreactive inclusions and this reliable measure of alpha-synuclein aggregation acts as a valuable index of the anti-aggregation effects (Masliah et al. Science (2000) 287:1265).

[0117] Analysis of patterns of neurodegeneration is achieved by analyzing synaptic and dendritic densities in the hippocampus, frontal cortex, temporal cortex and basal ganglia utilizing vibratome sections double-immunolabeled for synaptophysin and microtubule-associated protein 2 (MAP2) and visualized with LSCM. Additional analysis of neurodegeneration is achieved by determining tyrosine hydroxylase (TH) immunoreactivity in the caudoputamen and substantia nigra (SN) as previously described (Masliah, *et al.* (2000)). Sections will be imaged with the LSCM and each individual image is interactively thresholded such that the TH-immunoreactive terminals displaying pixel intensity within a linear range are included. A scale is set to determine the pixel to μm ratio. Then, this information is used to calculate the % area of the neuropil covered by TH-immunoreactive terminals. These same sections are also utilized to evaluate the numbers of TH neurons in the SN.

4. Analysis of Alpha-Synuclein in LBD patients

[0118] To determine which species of α -synuclein are enriched in or unique to disease tissue, we have examined brain samples from patients with multiple system atrophy (MSA) and a familial Parkinson's disease mutation (A53T; Contursi kindred). Particulate fractions of MSA and Contursi brain were prepared by homogenizing brain tissue in 50 mM Tris, 140 mM NaCl and either 1% Triton (MSA) or 0.1% NP40 (Contursi) respectively. Age matched, control patients ("normals") were prepared identically to the disease brain. Samples were analyzed on western blots of 1-D gels and by ELISA as described below, and also on 2-D gels. Part of the particulate fraction was analyzed. The rest was spun. The supernatant was also analyzed. The pellet was extracted in 7 M urea. The supernatant from this extraction was analyzed. The pellet was further extracted in 7 M urea/1% SDS. The supernatant was analyzed. Western blots using an antibody to detect total alpha-synuclein or to specifically alpha-synuclein phosphorylated at position 129 are shown in Fig. 11.

[0119] The synuclein fractionated differently in the Contursi versus control brain. Most of the synuclein in the normal brain was soluble after homogenization in tris buffered sucrose but almost all of the synuclein in the Contursi brain required urea plus SDS for solubilization suggesting a massive amount of Lewy bodies in this patient. The synuclein in the Contursi patient was strikingly different from that in the control patient in the amount of ser 129 phosphorylation. Only a small amount of phosphorylated α -synuclein was detected in the control patient, whereas the Contursi patient had an extremely large amount of phospho-synuclein by comparison on western blots. Thus, the insolubility of synuclein in the Contursi brain was associated with a large increase in synuclein phosphorylation at ser 129. The α -synuclein in

the Contursi patient also differed from that in normal brain in the distribution of C-terminal truncations. C-terminally truncated α -synuclein were observed in both control and Contursi particulate brain fraction. However, all detectable truncations were highly insoluble (urea/SDS extract) in the Contursi patient, whereas those in the control brain were soluble (tris buffered sucrose extract). The enrichment of the C-terminally truncated synuclein in a LB-enriched fraction of a Contursi patient is in agreement with our finding of C-terminally truncated synuclein enrichment in DLBD LBs. The MSA brain was also enriched in phospho (ser 129)- α -synuclein revealed C-terminal truncation and an abundance of phosphorylation and other acidic modifications also seen in LBs. High levels of phospho (ser 129) were also seen in the brain of an DLBD patient relative to an undiseased control. In a separate experiment, higher levels of phospho (ser 129) (about 30% higher) were also observed in PEAK cells transfected with alpha synuclein bearing an A53T mutation relative to PEAK cells transfected with wildtype human alpha synuclein.

5. Behavioral Analysis in a Transgenic Animal

[0120] For locomotor activity, mice are analyzed for 2 days in the rotarod (San Diego) Instruments, San Diego, CA), as previously described (Masliah, *et al.* (2000)). On the first day mice are trained for 5 trials: the first one at 10rpm, the second at 20rpm and the third to fifth at 40rpm. On the second day, mice are tested for 7 trials at 40rpm each. Mice are placed individually on the cylinder and the speed of rotation is increased from 0 to 40 rpm over a period of 240 sec. The length of time mice remain on the rod (fall Latency) is recorded and used as a measure of motor function.

[0121] Mice are tested for cognitive ability in the Morris Water maze (Morris, *Learn Motiv.* 12:239-260 (1981)). In this procedure, the animal is placed in a circular pool filled with water, with an escape platform submerged just below the surface of the water. A visible marker is placed on the platform so that the animal can find it by navigating toward a proximal visual cue. Alternatively, a more complex form of the test in which there are no formal cues to mark the platform's location will be given to the animals. In this form, the animal must learn the platform's location relative to distal visual cues. The length of time the animal remains in the water is inversely related to its cognitive ability.

6. Analysis of Aggregated Alpha-Synuclein Fragments in a Cell Line

[0122] GT1-7 neuronal cells (Hsue *et al.* *Am. J. Pathol.* 157:401-410 (2000)) are transfected with a pCR3.1-T expression vector (Invitrogen, Carlsbad, CA) expressing a truncated fragment of alpha-synuclein as described above murine alpha-synuclein and compared with cells transfected with expression vector alone. Cells transfected with vector alone have a fibroblastic appearance while cells transfected with alpha-synuclein are rounded, with inclusion bodies at the cell surface visible via both light and confocal scanning microscopy. Transfected GT1-7 cells can be used to screen agents for activity in clearing synuclein inclusions.

[0123] The above examples are illustrative only and do not define the invention; other variants will be readily apparent to those of ordinary skill in the art. The scope of the invention is encompassed by the claims of any patent(s) issuing herefrom.

Claims

1. An antibody that specifically binds to a 1-122 or 1-119 fragment of alpha-synuclein, without specifically binding to full-length alpha-synuclein as defined in SEQ ID No.1, or a fragment that induces this antibody wherein the fragment that induces the antibody has less than 20 amino acids of alpha-synuclein and includes the C-terminus of the 1-122 or 1-119 fragment of alpha-synuclein.
2. The antibody of claim 1 that is a human or humanized antibody, preferably of human isotype IgG1.
3. The antibody of claim 1 or claim 2, or the fragment that induces the antibody of claim 1, for use in the treatment or prophylaxis of Lewy body disease.
4. The antibody of claim 1 or claim 2 for use in diagnosing the presence or susceptibility to a LBD wherein the antibody is to be administered to a patient and the level of binding of the antibody in the patient is to be determined, wherein a higher level of binding relative to a base line level in undiseased individuals indicates presence or susceptibility to the LBD.
5. A fragment of full-length alpha-synuclein as defined in SEQ ID No.1, which is alpha-synuclein 1-122 or 1-119.
6. The fragment of claim 5, wherein the fragment of alpha-synuclein bears a mutation associated with a hereditary

Lewy Body Disease (LBD), optionally an A53T mutation.

7. A fragment of alpha-synuclein as defined in claim 5 or claim 6
either in combination with an adjuvant that augments an immune response comprising antibodies to the fragment,
or linked to a carrier forming a fusion protein, wherein the carrier augments an immune response comprising anti-
bodies to the fragment.
8. An *in vitro* method of screening for an agent having a pharmacological activity useful for treating a LBD comprising:
contacting the agent with a fragment of alpha-synuclein as defined in claim 5 or claim 6; and
determining the rate or extent of aggregation of the fragment of alpha-synuclein,
wherein a reduction in the rate or extent of aggregation relative to a control lacking the agent indicates the agent
has the pharmacological activity.
9. An *in vitro* method of screening an agent for a pharmacological activity useful in treating a LBD, comprising:
contacting a cell expressing alpha-synuclein and processing the alpha-synuclein into a fragment as defined in
claim 5 or claim 6 with said agent; and
determining a level of the fragment in the cell relative to a baseline level in the same cell type in the absence
of the agent,
a reduction in the level of the fragment relative to the baseline indicating the agent has the pharmacological
activity useful in treating a LBD;
wherein the cell is preferably a human cell, more preferably a neuronal cell or a dopaminergic cell.
10. A method of screening for an agent having a pharmacological activity useful for treating a LBD, comprising
contacting a non-human transgenic animal expressing a fragment of alpha-synuclein as defined in claim 5 or claim
6 with the agent; and
determining a level of aggregated forms of the fragment in the brain of the transgenic animal relative to a baseline
level of aggregated forms of the fragment in a comparable transgenic animal in the absence of the agent,
a reduction in the level of the aggregated forms fragment relative to the baseline indicating the agent has a phar-
macological activity useful in treating a LBD,
wherein the transgenic animal is preferably a mouse or a *Drosophila*.
11. A method of screening an agent for a pharmacological activity useful for treating a LBD, comprising
contacting a non-human transgenic animal having a transgene expressing alpha-synuclein and processing the
alpha-synuclein into a fragment as defined in claim 5 or claim 6 with the agent; and
determining a level of the fragment in a neuronal cell relative to a baseline level in the absence of the agent,
a reduction in the level of the fragments relative to the baseline indicating the agent has the pharmacological activity
useful for treating the LBD.
12. A transgenic non-human animal, preferably a mouse or *Drosophila*, having a genome comprising a transgene
comprising:
a promoter operably linked to a nucleic acid segment encoding a fragment of alpha-synuclein as defined in any
one of claim 5 or claim 6,
wherein expression of the fragment in the transgenic animal disposes the animal to develop at least one char-
acteristic of a LBD,
wherein the promoter is preferably a PDGF promoter, or
wherein the at least one characteristic is preferably an impairment of motor function or an impairment of cognitive
function.
13. An *in vitro* method of detecting presence or susceptibility to a LBD in a patient, comprising:
detecting a level of a fragment of alpha-synuclein as defined in claim 5 or claim 6 in a sample of cerebrospinal fluid,
a level greater than a baseline level in undiseased individuals indicating presence or susceptibility to LBD.
14. A method of screening for a protease that cleaves intact alpha-synuclein to form a fragment as defined in claim 5
or claim 6 comprising:

identifying an inhibitor of the protease;
 contacting the inhibitor with a cellular or tissue extract containing the protease, whereby the protease binds to the inhibitor; and
 releasing the protease from the inhibitor,

optionally wherein the inhibitor is a peptide of alpha-synuclein comprising a contiguous segment of at least 5 residues of intact alpha-synuclein between positions 115 and 130, preferably wherein the peptide comprises a contiguous segment of at least 5 residues between positions 118 and 122, more preferably wherein at least one of the residues is a transition state analog.

Patentansprüche

1. Antikörper, der spezifisch an ein 1-122- oder 1-119-Fragment von alpha-Synuclein bindet, ohne spezifisch an alpha-Synuclein mit voller Länge, wie in SEQ ID No.1 definiert, zu binden, oder Fragment, das diesen Antikörper induziert, wobei das Fragment, das den Antikörper induziert, weniger als 20 Aminosäuren von alpha-Synuclein aufweist und den C-Terminus des 1-122- oder 1-119-Fragments von alpha-Synuclein enthält.
2. Antikörper gemäß Anspruch 1, der ein menschlicher oder humanisierter Antikörper ist, vorzugsweise des menschlichen Isotyps IgG1.
3. Antikörper gemäß Anspruch 1 oder Anspruch 2 oder Fragment, das den Antikörper gemäß Anspruch 1 induziert, für die Verwendung bei der Behandlung oder Vorbeugung von Lewy-Körperchen-Krankheit.
4. Antikörper gemäß Anspruch 1 oder Anspruch 2 für die Verwendung zum Diagnostizieren des Vorhandenseins einer oder Anfälligkeit für eine LBD, wobei der Antikörper an einen Patienten zu verabreichen ist und das Bindungsniveau des Antikörpers in dem Patienten zu bestimmen ist, wobei ein höheres Bindungsniveau im Vergleich zu einem Grundlinienniveau in nicht erkrankten Individuen Vorhandensein der oder Anfälligkeit für die LBD anzeigt.
5. Fragment von alpha-Synuclein mit voller Länge, wie in SEQ ID No.1 definiert, das alpha-Synuclein 1-122 oder 1-119 ist.
6. Fragment gemäß Anspruch 5, wobei das Fragment von alpha-Synuclein eine Mutation trägt, die mit einer erblichen Lewy-Körperchen-Erkrankung (LBD) verbunden ist, gegebenenfalls eine A53T-Mutation.
7. Fragment von alpha-Synuclein gemäß Anspruch 5 oder Anspruch 6, entweder in Kombination mit einem Hilfsstoff, der eine Immunantwort verstärkt, umfassend Antikörper für das Fragment, oder verknüpft mit einem Träger, um ein Fusionsprotein zu bilden, wobei der Träger eine Immunantwort verstärkt, umfassend Antikörper für das Fragment.
8. In-vitro-Verfahren zum Screening nach einem Mittel mit einer pharmakologischen Aktivität, die zum Behandeln einer LBD nützlich ist, umfassend:
 Inkontaktbringen des Mittels mit einem Fragment von alpha-Synuclein gemäß Anspruch 5 oder Anspruch 6; und Bestimmen der Rate oder des Ausmaßes von Aggregation des Fragments von alpha-Synuclein, wobei eine Verringerung der Rate oder des Ausmaßes von Aggregation bezogen auf eine Kontrolle ohne das Mittel anzeigt, dass das Mittel die pharmakologische Aktivität aufweist.
9. In-vitro-Verfahren zum Screening eines Mittels auf eine pharmakologische Aktivität, die zum Behandeln einer LBD nützlich ist, umfassend:
 Inkontaktbringen einer Zelle, die alpha-Synuclein exprimiert und das alpha-Synuclein zu einem Fragment gemäß Anspruch 5 oder Anspruch 6 verarbeitet, mit dem Mittel; und Bestimmen der Menge des Fragments in der Zelle bezogen auf eine Grundlinienmenge in dem gleichen Zelltyp ohne das Mittel, wobei eine Verringerung der Menge des Fragments bezogen auf die Grundlinie anzeigt, dass das Mittel die pharmakologische Aktivität aufweist, die bei der Behandlung einer LBD nützlich ist;

wobei die Zelle vorzugsweise eine menschliche Zelle ist, bevorzugter eine neuronale Zelle oder eine dopaminerge Zelle.

- 5 10. Verfahren zum Screening nach einem Mittel mit einer pharmakologischen Aktivität, die zum Behandeln einer LBD nützlich ist, umfassend:

Inkontaktbringen eines nicht-menschlichen transgenen Tiers, das ein Fragment von alpha-Synuclein gemäß Anspruch 5 oder Anspruch 6 exprimiert, mit dem Mittel; und
 10 Bestimmen der Menge von aggregierten Formen des Fragments in dem Gehirn des transgenen Tiers bezogen auf eine Grundlinienmenge von aggregierten Formen des Fragments in einem vergleichbaren transgenen Tier ohne das Mittel,
 wobei eine Verringerung der Menge von aggregierten Formen des Fragments bezogen auf die Grundlinie anzeigt, dass das Mittel eine pharmakologische Aktivität aufweist, die bei der Behandlung einer LBD nützlich ist;
 wobei das transgene Tier vorzugsweise eine Maus oder eine Drosophila ist.

- 15 11. Verfahren zum Screening eines Mittels auf eine pharmakologische Aktivität, die zum Behandeln einer LBD nützlich ist, umfassend:

Inkontaktbringen eines nicht-menschlichen transgenen Tiers, das ein Transgen aufweist, das alpha-Synuclein exprimiert und das alpha-Synuclein zu einem Fragment gemäß Anspruch 5 oder Anspruch 6 verarbeitet, mit dem Mittel; und
 20 Bestimmen der Menge des Fragments in einer neuronalen Zelle bezogen auf eine Grundlinienmenge ohne das Mittel,
 wobei eine Verringerung der Menge des Fragments bezogen auf die Grundlinie anzeigt, dass das Mittel die pharmakologische Aktivität aufweist, die bei der Behandlung der LBD nützlich ist.

- 25 12. Transgenes nicht-menschliches Tier, vorzugsweise eine Maus oder eine Drosophila, mit einem Genom, das ein Transgen umfasst, das umfasst:

einen Promoter, der operabel mit einem Nukleinsäuresegment verknüpft ist, das ein Fragment von alpha-Synuclein gemäß einem von Anspruch 5 oder Anspruch 6 codiert,
 30 wobei Expression des Fragments in dem transgenen Tier bewirkt, dass das Tier wenigstens ein Charakteristikum einer LBD entwickelt,
 wobei der Promoter vorzugsweise ein PDGF-Promoter ist oder
 35 wobei das wenigstens eine Charakteristikum vorzugsweise eine Beeinträchtigung von motorischer Funktion oder eine Beeinträchtigung von kognitiver Funktion ist.

- 40 13. *In-vitro*-Verfahren zum Nachweisen von Vorhandensein einer oder Anfälligkeit für eine LBD in einem Patienten, umfassend:

Nachweisen der Menge eines Fragments von alpha-Synuclein gemäß Anspruch 5 oder Anspruch 6 in einer Probe von Zerebrospinalfluid,
 wobei eine Menge, die größer ist als eine Grundlinienmenge in nicht erkrankten Individuen, Vorhandensein von oder Anfälligkeit für LBD anzeigt.

- 45 14. Verfahren zum Screening auf eine Protease, die intaktes alpha-Synuclein spaltet, um ein Fragment gemäß Anspruch 5 oder Anspruch 6 zu bilden, umfassend:

Identifizieren eines Inhibitors der Protease;
 50 Inkontaktbringen des Inhibitors mit einem zellulären oder Gewebeextrakt, der die Protease enthält, wodurch die Protease an den Inhibitor bindet; und
 Freisetzen der Protease von dem Inhibitor,
 gegebenenfalls wobei der Inhibitor ein Peptid von alpha-Synuclein ist, das ein zusammenhängendes Segment von wenigstens 5 Resten von intaktem alpha-Synuclein zwischen den Positionen 115 und 130 umfasst, vorzugsweise wobei das Peptid ein zusammenhängendes Segment von wenigstens 5 Resten zwischen den Po-
 55 sitionen 118 und 122 umfasst, bevorzugter wobei wenigstens einer der Reste ein Übergangszustand-Analogen ist.

Revendications

1. Anticorps qui se lie spécifiquement à un fragment 1-122 ou 1-119 de l'alpha-synucléine, sans se lier spécifiquement à l'alpha-synucléine de longueur complète comme défini par SEQ ID No. 1, ou un fragment qui induit cet anticorps, où le fragment qui induit l'anticorps comporte moins de 20 acides aminés de l'alpha-synucléine et inclut l'extrémité C du fragment 1-122 ou 1-119 de l'alpha-synucléine.
2. Anticorps selon la revendication 1 qui est un humain ou un anticorps humanisé, préférentiellement de l'isotype IgG1 humain.
3. Anticorps selon la revendication 1 ou la revendication 2, ou fragment induisant l'anticorps selon la revendication 1, pour utilisation dans le traitement prophylactique ou thérapeutique de la démence à corps de Lewy.
4. Anticorps selon la revendication 1 ou la revendication 2 pour utilisation dans le diagnostic de la présence ou de la sensibilité à une démence à corps de Lewy, où l'anticorps doit être administré à un patient et le niveau de liaison de l'anticorps chez le patient doit être déterminé, où un niveau supérieur de liaison par rapport à un niveau de base chez des individus non malades indique la présence ou la sensibilité à la démence à corps de Lewy.
5. Fragment d'alpha-synucléine de longueur complète comme défini dans la SEQ ID No. 1, qui est l'alpha-synucléine 1-122 ou 1-119.
6. Fragment selon la revendication 5, où le fragment d'alpha-synucléine porte une mutation associée à une démence à corps de Lewy (DCL), éventuellement une mutation A53T.
7. Fragment d'alpha-synucléine selon la revendication 5 ou la revendication 6 soit en combinaison avec un adjuvant qui amplifie une réponse immunitaire comprenant des anticorps dirigés contre le fragment, soit lié à un vecteur pour former une protéine de fusion, où le vecteur augmente une réponse immunitaire comprenant des anticorps dirigés contre le fragment.
8. Méthode *in vitro* de recherche par criblage d'un agent ayant une activité pharmacologique utile dans le traitement d'une démence à corps de Lewy comprenant :
 - la mise en contact de l'agent avec un fragment d'alpha-synucléine selon la revendication 5 ou la revendication 6 ; et
 - la détermination du taux ou de l'étendue de l'agrégation du fragment d'alpha-synucléine, où une réduction du taux ou de l'étendue de l'agrégation par rapport à un témoin ne contenant pas l'agent indique que l'agent présente l'activité pharmacologique.
9. Méthode *in vitro* de recherche par criblage d'un agent ayant une activité pharmacologique utile dans le traitement d'une démence à corps de Lewy comprenant :
 - la mise en contact d'une cellule exprimant l'alpha-synucléine et la transformation de l'alpha-synucléine en un fragment selon la revendication 5 ou la revendication 6 ; et
 - la détermination d'un niveau du fragment dans la cellule par rapport à un niveau de base dans le même type de cellule en l'absence de l'agent, une réduction du niveau du fragment par rapport à la ligne de base, indiquant que l'agent présente l'activité pharmacologique utile dans le traitement d'une démence à corps de Lewy ;
 - où la cellule est préférentiellement une cellule humaine, plus préférentiellement une cellule neuronale ou une cellule dopaminergique.
10. Méthode de recherche par criblage d'un agent ayant une activité pharmacologique utile dans le traitement d'une démence à corps de Lewy, comprenant :
 - la mise en contact d'un animal transgénique non humain exprimant un fragment d'alpha-synucléine selon la revendication 5 ou la revendication 6 avec l'agent ; et
 - la détermination d'un niveau de formes agrégées du fragment dans le cerveau de l'animal transgénique par rapport à un niveau de base des formes agrégées du fragment chez un animal transgénique comparable en

l'absence de l'agent,
 une réduction du niveau du fragment des formes agrégées par rapport à la ligne de base, indiquant que l'agent
 présente une activité pharmacologique utile dans le traitement d'une démence à corps de Lewy,
 où l'animal transgénique est préférentiellement une souris ou une drosophile.

5

- 11.** Méthode de recherche par criblage d'un agent ayant une activité pharmacologique utile dans le traitement d'une
 démence à corps de Lewy, comprenant :

10

la mise en contact d'un animal transgénique non humain comportant un transgène exprimant l'alpha-synucléine
 et la transformation de l'alpha-synucléine en un fragment selon la revendication 5 ou la revendication 6 avec
 l'agent ; et

la détermination d'un niveau du fragment dans une cellule neuronale par rapport un niveau de base en l'absence
 de l'agent,

15

une réduction du niveau des fragments par rapport à la ligne de base, indiquant que l'agent présente l'activité
 pharmacologique utile dans le traitement de la démence à corps de Lewy.

- 12.** Animal non humain transgénique, préférentiellement une souris ou une drosophile, comportant un génome com-
 prenant un transgène incluant :

20

un promoteur lié de façon fonctionnelle à un segment d'acide nucléique codant un fragment d'alpha-synucléine
 selon l'une quelconque de la revendication 5 ou la revendication 6,

où l'expression du fragment dans l'animal transgénique dispose l'animal à développer au moins une caracté-
 ristique d'une démence à corps de Lewy,

25

où le promoteur est préférentiellement un promoteur de PDGF, ou

où l'au moins une caractéristique est préférentiellement un déficit de la fonction motrice ou un déficit de la
 fonction cognitive.

- 13.** Méthode *in vitro* de détection de la présence ou de la sensibilité à une démence à corps de Lewy chez un patient,
 comprenant :

30

la détection d'un niveau d'un fragment d'alpha-synucléine selon la revendication 5 ou la revendication 6 dans
 un échantillon de fluide cérébrospinal,

un niveau supérieur à un niveau de base chez des individus non malades indiquant la présence ou la sensibilité
 à la démence à corps de Lewy.

35

- 14.** Méthode de recherche par criblage d'une protéase qui clive l'alpha-synucléine intacte pour former un fragment selon
 la revendication 5 ou la revendication 6 comprenant :

40

l'identification d'un inhibiteur de la protéase ;

la mise en contact de l'inhibiteur avec un extrait de cellule ou de tissu contenant la protéase, ce par quoi la
 protéase se lie à l'inhibiteur ; et

la libération de la protéase d'avec l'inhibiteur, éventuellement où l'inhibiteur est un peptide d'alpha-synucléine
 comprenant un segment contigu d'au moins 5 résidus d'alpha-synucléine intacte entre les positions 115 et 130,
 préférentiellement où le peptide comprend un segment contigu d'au moins 5 résidus entre les positions 118 et

45

122, plus préférentiellement où au moins l'un des résidus est un analogue dans un état de transition.

50

55

3mo mouse: cortex/hippocampus





Fig. 1B

Human alpha synuclein preferential Ab

Fig. 1A

Fig. 2
synuclein mouse: cortex and hippocampus
ELADW-47 (aa 115 - 122) 1:300






Fig. 4
synuclein mouse: cortex and hippocampus
12C1 (aa 43-51; 58-65) 1:300




Fig. 5A






Fig. 5B




ELADW-44

Fig. 5D




ELADW-48

Fig. 5C



ELADW-47

Fig. 5E



8A5
(free C-term)

ELADW43 (aa 1 free amino terminus) 8A5 (aa 140 free carboxy terminus)




Fig. 6A





Fig. 6B



Syn-1 (aa 91-96) Fig. 6C

Reprobe of immunoblots of Tris Soluble proteins w/ C-terminal antibodies




Fig. 7A

Syn-1 (aa 91-96)




Fig. 7C

5C12 (aa 109-120)




Fig. 7B

ELADW47 (aa 118-123)




Fig. 7D

LB509 (aa 115-123)





Fig. 8

Our First Lewy body blots



Lewy body blot 40 ug Syn-1 antibody

Tris soluble proteins (P23) Syn-1 Auto rad

Fig. 9B

Fig. 9A

élan

Reprobe of immunoblots of Lewy body UTC extracts w/ C-terminal antibodies




Fig. 10A

Syn-1 (aa 91-96)




Fig. 10C

5C12 (aa 115-120)




Fig. 10B

ELADW47 (aa 118-123)



Fig. 10D

LB509 (aa 115-125)




Fig. 11A

Fig. 11B

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 5811633 A [0053]
- US 5612486 A, McConlogue [0053]
- WO 9512608 A [0063]
- WO 9306121 A [0063]
- WO 9408051 A [0063]
- WO 9535503 A [0063]
- WO 9530642 A [0063]
- WO 9118980 A [0063]
- WO 9007861 A [0071]
- US 5693762 A [0071]
- US 5693761 A [0071]
- US 5585089 A [0071]
- US 5530101 A [0071]
- US 5225539 A, Winter [0071]
- WO 9222653 A, Carter [0071]
- US 4634664 A, Oestberg [0072]
- US 4634666 A, Engleman [0072]
- WO 931222 A, Lonberg [0072]
- US 5877397 A [0072]
- US 5874299 A [0072]
- US 5814318 A [0072]
- US 5789650 A [0072]
- US 5770429 A [0072]
- US 5661016 A [0072]
- US 5633425 A [0072]
- US 5625126 A [0072]
- US 5569825 A [0072]
- US 5545806 A [0072]
- WO 9110741 A, Kucherlapati [0072]
- WO 9117271 A, Dower [0072]
- WO 9201047 A, McCafferty [0072]
- US 5877218 A [0072]
- US 5871907 A [0072]
- US 5858657 A [0072]
- US 5837242 A [0072]
- US 5733743 A [0072]
- US 5565332 A [0072]
- US 60423012 B [0080]
- US 0015239 W [0080]
- US 0334527 W [0080]
- GB 2220211 A [0092]
- US 5057540 A [0092]
- WO 9840100 A [0092]
- WO 9014837 A [0093]
- US 4855283 A [0094]

Non-patent literature cited in the description

- **MCKEITH et al.** Clinical and pathological diagnosis of dementia with Lewy bodies (DLB): Report of the CDLB International Workshop. *Neurology*, 1996, vol. 47, 1113-24 [0001]
- **GALASKO et al.** Clinical-neuropathological correlations in Alzheimer's disease and related dementias. *Arch. Neurol.*, 1994, vol. 51, 888-95 [0001]
- **TANNER et al.** Epidemiology of Parkinson's disease and akinetic syndromes. *Curr. Opin. Neurol.*, 2000, vol. 13, 427-30 [0001]
- **SPILLANTINI et al.** *Nature*, 1997, vol. 388, 839-40 [0003]
- **TAKEDA et al.** *J. Pathol.*, 1998, vol. 152, 367-72 [0003]
- **WAKABAYASHI et al.** *Neurosci. Lett.*, 1997, vol. 239, 45-8 [0003]
- **KRUGER et al.** *Nature Gen.*, 1998, vol. 18, 106-8 [0003]
- **POLYMERPOULOS et al.** *Science*, 1997, vol. 276, 2045-7 [0003]
- **MASLIAH et al.** *Science*, 2000, vol. 287, 1265-9 [0003]
- **FEANY et al.** *Nature*, 2000, vol. 404, 394-8 [0003] [0053]
- **IWAI A.** *Biochim. Biophys. Acta*, 2000, vol. 1502, 95-109 [0004]
- **MASLIAH et al.** *AM. J. Pathol.*, 1996, vol. 148, 201-10 [0004]
- **UEDA et al.** *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 11282-6 [0004] [0046]
- **HARLOW ; LANE.** Antibodies, A Laboratory Manual. Cold Spring Harbor Publications, 1988 [0028]
- **SMITH ; WATERMAN.** *Adv. Appl. Math.*, 1981, vol. 2, 482 [0030]
- **NEEDLEMAN ; WUNSCH.** *J. Mol. Biol.*, 1970, vol. 48, 443 [0030]
- **PEARSON ; LIPMAN.** *Proc. Nat'l. Acad. Sci. USA*, 1988, vol. 85, 2444 [0030]
- **ALTSCHUL et al.** *J. Mol. Biol.*, 1990, vol. 215, 403-410 [0031]
- **HENIKOFF ; HENIKOFF.** *Proc. Natl. Acad. Sci. USA*, 1989, vol. 89, 10915 [0031]
- **KARLIN ; ALTSCHUL.** *Proc. Nat'l. Acad. Sci. USA*, 1993, vol. 90, 5873-5787 [0032]

- **SONGSIVILAI ; LACHMANN.** *Clin. Exp. Immunol.*, 1990, vol. 79, 315-321 [0035]
- **KOSTELNY et al.** *J. Immunol.*, 1992, vol. 148, 1547-1553 [0035]
- **STAHLI et al.** *Methods in Enzymology*, 1983, vol. 9, 242-253 [0038]
- **KIRKLAND et al.** *J. Immunol.*, 1986, vol. 137, 3614-3619 [0038]
- **HARLOW ; LANE.** *Antibodies, A Laboratory Manual.* Cold Spring Harbor Press, 1988 [0038]
- **MOREL et al.** *Molec. Immunol.*, 1988, vol. 25 (1), 7-15 [0038]
- **CHEUNG et al.** *Virology*, 1990, vol. 176, 546-552 [0038]
- **MOLDENHAUER et al.** *Scand. J. Immunol.*, 1990, vol. 32, 77-82 [0038]
- **IWAI et al.** *Biochemistry*, vol. 34, 10139-10145 [0049]
- **JENSEN et al.** *Biochem. J.*, 1995, vol. 310, 91-94 [0049]
- **SAMBROOK et al.** *Molecular Cloning: A Laboratory Manual.* C.S.H.P. Press, 1989 [0051]
- **MCKEITH et al.** *Clinical and pathological diagnosis of dementia with Lewy bodies (DLB): Report of the CDLB International Workshop. Neurology*, 1996, vol. 47, 1113-24 [0052]
- **MASLIAH et al.** *Am. J. Pathol.*, 1996, vol. 148, 201-10 [0053]
- **GAMES et al.** *Nature*, 1995, vol. 373, 523 [0053]
- **HSIAO et al.** *Science*, 1996, vol. 274, 99 [0053]
- **STAUFENBIEL et al.** *Proc. Natl. Acad. Sci. USA*, 1997, vol. 94, 13287-13292 [0053]
- **STURCHLER-PIERRAT et al.** *Proc. Natl. Acad. Sci. USA*, 1997, vol. 94, 13287-13292 [0053]
- **BORCHELT et al.** *Neuron*, 1997, vol. 19, 939-945 [0053]
- **MASLIAH et al.** *PNAS USA*, 2001, vol. 98, 12245-12250 [0053]
- **GAMES et al.** *Transgenic animals of the invention are preferably rodents, such as mice or rats, or insects, such as Drosophila* [0053]
- **HSUE et al.** *Am. J. Pathol.*, 2000, vol. 157, 401-410 [0055] [0122]
- **WOOD.** *J. Biol. Chem.*, 1999, vol. 274, 19509-19512 [0057]
- **HARLOW ; LANE.** *Antibodies, A Laboratory Manual.* CSHP, 1988 [0069]
- **QUEEN et al.** *Proc. Natl. Acad. Sci. USA*, 1989, vol. 86, 10029-10033 [0071]
- **OESTBERG et al.** *Hybridoma*, 1983, vol. 2, 361-367 [0072]
- *Nature*, 1994, vol. 148, 1547-1553 [0072]
- *Nature Biotechnology*, 1996, vol. 14, 826 [0072]
- **KENSIL et al.** *Vaccine Design: The Subunit and Adjuvant Approach.* Plenum Press, 1995 [0092]
- **STOUTE et al.** *N. Engl. J. Med.*, 1997, vol. 336, 86-91 [0092]
- **CHANG et al.** *Advanced Drug Delivery Reviews*, 1998, vol. 32, 173-186 [0095]
- *Remington's Pharmaceutical Science.* Mack Publishing Company, 1980 [0096]
- **LANGER.** *Science*, 1990, vol. 249, 1527 [0099]
- **HANES.** *Advanced Drug Delivery Reviews*, 1997, vol. 28, 97-119 [0099]
- **GLENN et al.** *Nature*, 1998, vol. 391, 851 [0101]
- **PAUL et al.** *Eur. J. Immunol.*, 1995, vol. 25, 3521-24 [0101]
- **CEVC et al.** *Biochem. Biophys. Acta*, 1998, vol. 1368, 201-15 [0101]
- **JENSEN et al.** *J. Biol. Chem.*, 2000, vol. 275, 21500-21507 [0108]
- **MASLIAH et al.** *Science*, 2000, vol. 287, 1265 [0115] [0116]
- **MORRIS.** *Learn Motiv.*, 1981, vol. 12, 239-260 [0121]

ALFA-SZINUKLEIN CSONKOLT FRAGMENTEI LEWY-TESTES BETEGSÉGBEN

Szabadalmi igénypontok

1. Ellenanyag, amely specifikusan kötődik alfa-szinukleín 1-122 vagy 1-119 fragmentéhez anélkül, hogy specifikusan kötődne a SEQ ID No. 1 szerinti szekvencia által meghatározott teljes hosszúságú alfa-szinukleín-hez, vagy fragment, amely ezt az ellenanyagot indukálja, ahol a fragment, amely indukálja az ellenanyagot, az alfa-szinukleín kevesebb, mint 20 aminosavját tartalmazza, és tartalmazza az alfa-szinukleín 1-122 vagy 1-119 fragmentének C-terminálisát.

2. Az 1. igénypont szerinti ellenanyag, amely emberi vagy humanizált ellenanyag, előnyösen emberi IgG1 izotípus.

3. Az 1. vagy 2. igénypont szerinti ellenanyag vagy a fragment, amely indukálja az 1. igénypont szerinti ellenanyagot, Lewy-testes betegség kezelésében vagy megelőzésében történő alkalmazásra.

4. Az 1. vagy 2. igénypont szerinti ellenanyag LBD (Lewy-testes betegség) jelenlétének vagy arra való fogékonyságnak diagnosztizálásában történő alkalmazásra, ahol az ellenanyag beadandó egy páciensnek, és a páciensben az ellenanyag kötődésének szintje meghatározandó, ahol a betegségtől mentes személyekben lévő alapszinthez képest magasabb kötődési szint LBD jelenlétét vagy arra való fogékonyságot jelez.

5. A SEQ ID No. 1 szerinti szekvencia által meghatározott teljes hosszúságú alfa-szinukleín fragmente, amely az 1-122 vagy 1-119 alfa-szinukleín.

6. Az 5. igénypont szerinti fragment, ahol az alfa-szinukleín fragmente örökletes Lewy-testes betegséggel (LBD) összefüggő mutációt hordoz, előnyösen A53T mutációt.

7. Az 5. vagy 6. igénypontban meghatározott alfa-szinukleín fragment, a fragment elleni ellenanyagokat tartalmazó immunválaszt fokozó adjuvánssal való kombinációban vagy hordozóhoz kapcsolva, ezáltal fúziós fehérjét kialakítva, ahol a hordozó a fragment elleni ellenanyagokat tartalmazó immunválaszt fokozza.

8. *In vitro* eljárás LBD kezelésében alkalmazható farmakológiai aktivitású ágens szkrínelésére, amely tartalmazza a következőket:

az ágens érintkeztetése az 5. vagy 6. igénypontban meghatározott alfa-szinukleín fragmenttel és

az alfa-szinukleín fragment aggregációja arányának vagy kiterjedésének meghatározása,

ahol az ágens nem tartalmazó kontrollhoz képest az aggregáció arányának vagy kiterjedésének csökkenése azt jelzi, hogy az ágens rendelkezik a farmakológiai aktivitással.

9. *In vitro* eljárás ágens LBD kezelésében alkalmazható farmakológiai aktivitásának szkrínelésére, amely tartalmazza a következőket:

alfa-szinukleint expresszálo és az alfa-szinukleint az 5. vagy 6. igénypontban meghatározott fragmentté feldolgozó sejt érintkeztetése az ágenssel és

a sejtben a fragment szintjének meghatározása ugyanolyan sejttypusban az ágens hiányában jelenlévő alapszinthez képest,

az alapszinthez képest a fragment szintjének csökkenése jelzi, hogy az ágensnek van LBD kezelésében alkalmazható farmakológiai aktivitása,

ahol a sejt előnyösen emberi sejt, előnyösebben neuronális sejt vagy dopaminerg sejt.

10. Eljárás LBD kezelésében alkalmazható farmakológiai aktivitású ágens szkrinelésére, amely tartalmazza a következőket:

az 5. vagy 6. igénypontban meghatározott alfa-szinukleín fragmenst expresszáló, embertől különböző transzgenikus állat érintkeztetése az ágenssel és

a transzgenikus állat agyában a fragmens aggregált formája szintjének meghatározása összehasonlításra alkalmas transzgenikus állatban a fragmens aggregált formájának az ágens hiányában jelenlévő alapszintjéhez képest,

az alapszinthez képest a fragmens aggregált formája szintjének csökkenése jelzi, hogy az ágensnek van LBD kezelésében alkalmazható farmakológiai aktivitása,

ahol a transzgenikus állat előnyösen egér vagy *Drosophila*.

11. Eljárás ágens LBD kezelésében alkalmazható farmakológiai aktivitásának szkrinelésére, amely tartalmazza a következőket: alfa-szinukleint expresszáló transzgent tartalmazó és az alfa-szinukleint az 5. vagy 6. igénypontban meghatározott fragmenssé feldolgozó, embertől különböző transzgenikus állat érintkeztetése az ágenssel és

a fragmens szintjének meghatározása neuronális sejtekben az ágens hiányában jelenlévő alapszinthez képest,

az alapszinthez képest a fragmens szintjének csökkenése jelzi, hogy az ágensnek van LBD kezelésében alkalmazható farmakológiai aktivitása.

12. Transzgenikus, embertől különböző állat, előnyösen egér vagy *Drosophila*, melynek genomja tartalmaz következőt tartalmazó transzgent:

az 5. vagy 6. igénypontban meghatározott alfa-szinukleín fragmenst kódoló nukleinsav-szegmenshez működőképesen kapcsolt promóter,

ahol a fragmens expressziója a transzgenikus állatban megfosztja az állatot attól, hogy LBD legalább egy jellemzője kifejlődjön benne,

ahol a promóter előnyösen PDGF promóter vagy

ahol a legalább egy jellemző előnyösen motoros funkció károsodása vagy kognitív funkció károsodása.

13. *In vitro* eljárás páciensben LBD jelenlétének vagy arra való fogékonyság kimutatására, amely tartalmazza

az 5. vagy 6. igénypontban meghatározott alfa-szinukleín fragmens szintjének kimutatását cerebrospinális folyadékban,

ahol a betegségtől mentes személyekben mérhető alapszinthez képest nagyobb szint LBD jelenlétét vagy arra való fogékonyságot jelez.

14. Eljárás olyan proteáz szkrinelésére, amely intakt alfa-szinukleint hasít, hogy az 5. vagy 6. igénypontban meghatározott fragmenst kialakítsa, amely tartalmazza a következőket:

a proteáz inhibitorának azonosítása,

az inhibitor érintkeztetése a proteázt tartalmazó sejtes vagy szöveti kivonattal, ahol a proteáz kötődik az inhibitorhoz és

a proteáz felszabadítása az inhibitorról,

adott esetben ahol az inhibitor alfa-szinukleín-peptid, amely intakt alfa-szinukleín 115. és 131. pozíciói közötti legalább 5 aminosavból álló folyamatos szegmenst tartalmaz, előnyösen ahol a peptid a 118. és 122. pozíciók közötti legalább 5 aminosavból álló folyamatos szegmenst tartalmaz, előnyösebben ahol az aminosavak legalább egyike tranzíciós állapotú analóg.